EAST

10/723,478

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3146	((546/268.1,280.1,281.1,300) or (514/210.2,337,351)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/12/12 13:38

		Results
1.	TITLE-ABSTR-KEY(sri or serotonin) and TITLE-ABSTR-KEY(premature ejaculation) *[All Sources(- All Sciences -)]*	13

results **1 - 13**

13 Articles Found

TITLE-ABSTR-KEY(sri or serotonin) and TITLE-ABSTR-KEY(premature ejaculation)

1. **Premature ejaculation: defining sex in the absence of context** • **ARTICLE**
*The Journal of Men's Health & Gender, **In Press, Corrected Proof**, Available online 1 December 2005,*
Martin J. Steggall and Anthony Pryce
Abstract

Medical and psychiatric literature defines premature, early or rapid ejaculation from diverse perspectives and provides explanations and treatment options that reflect their historical development. Medical discourse focuses on **premature ejaculation** as a neuro-biological phenomenon with a growing 'evidence' base emerging for both defining the condition and treating it with selective **serotonin** re-uptake inhibitors (SSRIs).

Current definitions of **premature ejaculation** however are difficult to deploy clinically; 'marked interpersonal distress' is a subjective measure and not all men are able (or willing) to time their sexual activity with a stopwatch. The addition of a defined measure of intravaginal ejaculatory latency time (IELT) is, perhaps, useful for research, but less so for the individual men with **premature ejaculation.** Psychiatric literature considers the diagnosis and management of **premature ejaculation** from a behavioural perspective, where the man learnt 'hurriedly' and therefore got into a pattern of hurried sexual activity, although there is no compelling data (or evidence) that adoption of behavioural therapies are successful in providing a 'cure' for the problem.

Both medical and psychological perspectives appear based on certain assumptions, i.e. that of the construction of 'normal' sexual activity and function. Neither medical rationalities nor psychological perspectives consider the *person* who is the premature ejaculator, and both generally fail to consider his social contexts and cultural meanings or the anxieties of managing gender-determined role performances. Similarly, the 'irrationalities' of erotic desire, intimacy and embodiment remain largely marginal or invisible elements in the pursuit of 'evidence'.

Whilst there is little sociological literature on the topic, **premature ejaculation** provides an example, *par excellence*, of an aspect of human experience that demonstrates the paradigmatic tensions between medical positivism and the cultural constructions of experience. This paper seeks to discuss **premature ejaculation** from another perspective, problematising the complexities of sometimes contradictory, social, sexual and gendered identities, and reflecting on a number of key areas that seem absent from the clinical literature on **premature ejaculation.**

2. **Differential effects of simultaneous or sequential administration of paroxetine and WAY-100,635 on ejaculatory behavior** • **ARTICLE**
*Pharmacology Biochemistry and Behavior, **In Press, Corrected Proof**, Available online 25 October 2005,*

C. Looney, K.B. Thor, D. Ricca and L. Marson
SummaryPlus | Full Text + Links | PDF (138 K)

Clinical treatment of depression or anxiety with selective **serotonin** reuptake inhibitors (SSRIs) often results in delayed ejaculation or anorgasmia. Co-treatment with subtype-selective **serotonin** receptor antagonists may alter the timing of onset of action and potentiate or reduce sexual side effects. Sexual behavior in male Sprague–Dawley rats was examined after acute administration of the SSRI, paroxetine and the **serotonin**$_{1A}$ antagonist, WAY-100,635. Acute administration of paroxetine alone did not alter male ejaculatory behavior. However, administration of paroxetine plus WAY-100,635 resulted in a significant delay in mounting behavior and increased the time to ejaculation. Simultaneous administration of paroxetine and WAY-100,635 produced a greater delay in initiation of mounting behavior and ejaculation compared to sequential administration of paroxetine followed by WAY-100,635. The differential effect on sexual behavior or addition of specific **serotonin** receptor antagonists may be relevant for clinical treatment therapies of **premature ejaculation.**

---

3. **Lifelong premature ejaculation: current debate on definition and treatment** • **ARTICLE**
The Journal of Men's Health & Gender, Volume 2, Issue 3, September 2005, Pages 333-338
Marcel D. Waldinger
Abstract

Lifelong **premature ejaculation** is characterized by early ejaculations occurring at nearly every intercourse, with nearly every female partner, and most often from the first sexual encounters in puberty and adolescence. **Premature ejaculation** has always been regarded as a psychological disorder that had to be treated by psychotherapy. However, there is no evidence supporting general psychological causes and efficacy of behavioural treatment for this male sexual complaint. In contrast, there is increasing evidence for the efficacy of daily treatment with some selective **serotonin** reuptake inhibitors (SSRIs) and on-demand treatment with clomipramine and anesthetic ointments. Data of recent epidemiological stopwatch research of the intravaginal ejaculation latency time (IELT) support an ejaculation distribution theory, of a continuum of IELT in the general male population. Using the 0.5 and 2.5 percentile as accepted standards of disease definition, lifelong **premature ejaculation** has been defined as a neurobiological dysfunction with an unacceptable increase of risk to develop sexual and psychological problems at any time during a lifetime. It is proposed that all men with an IELT of less than 1 minute have "definite" **premature ejaculation,** while men with IELTs between 1 and 1.5 minutes have "probable" **premature ejaculation.** In addition, it is proposed to define the severity of **premature ejaculation** (none, mild, moderate, severe) in terms of associated psychological problems.

---

4. **Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130** • **ARTICLE**
Pharmacology Biochemistry and Behavior, Volume 80, Issue 3, March 2005, Pages 521-528
Matthew T. Taber, Robert N. Wright, Thaddeus F. Molski, Wendy J. Clarke, Patrick J. Brassil, Derek J. Denhart, Ronald J. Mattson and Nicholas J. Lodge
SummaryPlus | Full Text + Links | PDF (167 K)

BMS-505130 is a potent and selective **serotonin** transport inhibitor; K_i for binding to the **serotonin** transporter=0.18 nM (K_i values for binding to the norepinephrine and dopamine transporters=4.6 and 2.1 μM, respectively). In platelet **serotonin** uptake studies BMS-505130 (5 mg/kg, p.o.) produced a robust inhibition of **serotonin** uptake. In microdialysis studies oral dosing with BMS-505130 produced a dose-dependent increase in cortical **serotonin** levels that reached a maximal effect of 200% above baseline at a dose of 1 mg/kg, p.o.; the peak **serotonin** response was transient in nature. Following oral administration, peak plasma concentrations of BMS-505130 reached Tmax at 1.6±0.7 h and then declined to concentrations <10% of Cmax within the following 6 h; plasma half-life following i.v. dosing was 0.46±0.02 h. Parallel microdialysis and pharmacokinetic studies revealed that changes in **serotonin** levels in the cortex mirrored changes in the brain concentration of BMS-505130. In a behavioral assay known to be sensitive to selective **serotonin** reuptake inhibitors

(SSRIs), mouse tail suspension, BMS-505130 produced a robust response after either oral or intraperitoneal dosing. BMS-505130 exhibits a pharmacological, neurochemical and behavioral profile consistent with a potent SSRI. Moreover, BMS-505130's short half-life may be advantageous for the treatment of **premature ejaculation** where an acute effect to delay ejaculation followed by a relatively rapid fall in SSRI plasma concentrations might be desirable.

---

5. ☐ **On-Demand Treatment of Premature Ejaculation with Clomipramine and Paroxetine: A Randomized, Double-Blind Fixed-Dose Study with Stopwatch Assessment** • **ARTICLE**
European Urology, Volume 46, Issue 4, October 2004, Pages 510-516
Marcel D. Waldinger, Aeilko H. Zwinderman and Berend Olivier
SummaryPlus | Full Text + Links | PDF (123 K)

Objective: To investigate the degree of ejaculation delay induced by on-demand treatment with 20 mg paroxetine and 25 mg clomipramine and to assess the type and severity of non-sexual side-effects of treatment at the day of and the day after treatment with these drugs.

Method: A randomized, double-blind, fixed-dose, on-demand study in 30 men with lifelong **premature ejaculation** was performed. During a 1-month baseline period and a 4-week drug treatment period patients assessed the intravaginal ejaculation latency time (IELT) at home with a stopwatch. Only men with an IELT <1 min were randomly assigned to drug treatment. Patients assessed the drug coitus interval time (DCIT) and used the UKU side effect scale questionnaire at baseline, the day of and the day after intercourse.

Results: On-demand treatment with 25 mg clomipramine, with a mean DCIT of 5.14 h, led to a 4.05 (95%CI: 3.26–5.02) fold-increase of the IELT. On-demand treatment with 20 mg paroxetine, with a mean DCIT of 5.39 h, led to a 1.41 (95%CI: 1.22–1.63) fold-increase of the IELT. Both drugs had a high incidenc of non-sexual side effects at the coitus day and the next day. At the day of coitus paroxetine led to significant sleepiness and yawning compared to clomipramine. At the day after coitus clomipramine induced significant nausea compared to paroxetine.

Conclusion: On-demand treatment with 25 mg clomipramine led to a clinical relevant ejaculation delay. In contrast, 20 mg paroxetine had no clinical relevant ejaculation delay in men with lifelong **premature ejaculation** with an IELT of less than 1 minute. Both drugs exert mostly mild yet annoying non-sexual side effects both at the coitus day and the next day.

---

6. ☐ **Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation** • **ARTICLE**
Urology, Volume 61, Issue 1, January 2003, Pages 197-200
Juza Chen, Nicola J. Mabjeesh, Haim Matzkin and Alexander Greenstein
SummaryPlus | Full Text + Links | PDF (108 K)

Objectives

To evaluate the efficacy of sildenafil and selective **serotonin** reuptake inhibitor in alleviating **premature ejaculation** (PE) in patients in whom other treatments had failed.

Methods

Healthy men evaluated for primary PE graded their ejaculation on a scale of 0 to 8 (0 = almost never, 8 = almost always). The intravaginal ejaculatory latency time (IVELT) was graded on a scale of 0 to 3 (0 = longer than 5 minutes, 3 = shorter than 1 minute). The 138 men who scored their PE as 4 or greater and IVELT as 2 or greater comprised the study group. Psychological and behavioral counseling was provided during the study. PE was graded using the same scales 3 months after the initiation of each treatment. Topical 5% lidocaine ointment comprised the initial treatment:

dissatisfied patients (PE grade 4 or greater, IVELT 2 or greater), took one tablet of paroxetine 20 mg for 30 days and then one tablet 7 hours before intercourse. Sildenafil was added to the treatment of patients dissatisfied with paroxetine alone.

Results

The mean initial PE grade was 5.67 ± 0.13 and that for IVELT was 2.9 ± 0.19 for all participants (mean age 28.7 years). Thirty-eight reported improvement (PE grade 2.0 ± 0.8, $P < 0.01$; IVELT 0.13 ± 0.34, $P < 0.001$) after local lidocaine application. Of the 100 treated with paroxetine, 42 reported improvement (PE grade 2.5 ± 0.1, $P < 0.01$; IVELT 0.28 ± 0.46, $P < 0.001$), and 56 of the remaining 58 who were treated with a combination of paroxetine and sildenafil reported improvement (PE grade 1.78 ± 0.23, $P < 0.001$; IVELT 0.16 ± 0.37, $P < 0.001$). Two patients remained dissatisfied with all treatment modalities.

Conclusions

Sildenafil combined with paroxetine and psychological and behavioral counseling alleviated PE in patients in whom other treatments failed.

---

7. **A bihormonal model of normal sexual stimulation; the etiology of premature ejaculation** • **ARTICLE**
Medical Hypotheses, Volume 57, Issue 1, July 2001, Pages 93-95
I. G. Motofei
Abstract | Abstract + References | PDF (102 K)

The physiological sexual excitation is mediated both by the sympathetic and the parasympathetic nervous system. The antagonism between testosterone (Tt) and estrogens (Es) as well as the fact that the dynamics of the sexual excitation in the male are antagonistic to those in the female are nowadays well-known; hence, the hypothesis was emitted that the sympathoparasympathetic sexual excitation is bihormonal mediated, consisting in a very active sexual hormone associated with a weak antagonistic hormone.

Most studies show a serotonergic (ejaculatory) involvement in **premature ejaculation** (PE). Nevertheless, an effective treatment of PE is rather difficult with selective **serotonin** reuptake inhibitor drugs and other clinical data even suggest that changes in PE actually involve at first the sexual excitation process and only secondly the ejaculation reflex.

Thus, a therapeutic model for PE is set up, starting from the physiological aspects described and from the presumed pathophysiological mechanism in PE.

---

8. **Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation** • **ARTICLE**
Urology, Volume 54, Issue 3, September 1999, Pages 544-547
Soo Woong Kim and Jae-Seung Paick
SummaryPlus | Full Text + Links | PDF (111 K)

Objectives. Pharmacotherapy using selective **serotonin** reuptake inhibitors (SSRIs) for men with primary **premature ejaculation** is promising. In particular, the strategy of taking a pill "as needed" may offer an attractive option. To investigate the possibility of self-therapy for the treatment of **premature ejaculation,** we compared the efficacy of sertraline taken as needed with that of continuous medication.

Methods. Since 1996, we have treated 24 men with sertraline on an as needed basis for primary **premature ejaculation.** Sertraline was chosen from among the SSRIs because a large dose need not be divided and because peak plasma levels occur 4 to 8 hours after oral administration, making 5 PM

a suitable time for administration (by which time a man may know whether sexual intercourse is likely to occur later that evening). Each patient was started on 50 mg daily for 2 weeks, and the dose was then adjusted to 50 or 100 mg on the day of intercourse only (PRN).

Results. After 6 weeks, 18 men were still taking medication, and 6 had dropped out. Among the 18, the mean ejaculation latency was 23 ± 19 seconds before treatment, 5.9 ± 4.2 minutes after 2 weeks of 50 mg daily, 5.1 ± 3.8 minutes after 2 weeks of 50 or 100 mg PRN, and 4.5 ± 2.7 minutes after 4 weeks of 50 or 100 mg PRN. Mean sexual satisfaction scores (5, extremely satisfied; 0, extremely unsatisfied) for men were 0.8 ± 0.8 before treatment, 3.8 ± 1.2 after 2 weeks of 50 mg daily, 3.4 ± 1.0 after 2 weeks of 50 or 100 mg PRN, and 3.2 ± 0.7 after 4 weeks of 50 or 100 mg PRN. For their partners, mean sexual satisfaction scores were 1.1 ± 0.7 before treatment, 3.2 ± 1.6 after 2 weeks of 50 mg daily, 3.1 ± 1.4 after 2 weeks of 50 or 100 mg PRN, and 3.3 ± 1.2 after 4 weeks of 50 or 100 mg PRN. Side effects were intermittent excessive delay of ejaculation in 1 patient, fatigue in 2, and numbness in 1.

Conclusions. If our results are supported by additional long-term clinical studies, self-therapy with sertraline taken PRN at 5 **PM** for the treatment of **premature ejaculation** could be as attractive as self-injection therapy for the treatment of erectile dysfunction.

---

9. ☒ **A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat** • **ARTICLE**

European Neuropsychopharmacology, Volume 9, Issues 1-2, 1 January 1999, Pages 123-135

Jan Mos, Ian Mollet, Jeroen T. B. M. Tolboom, Marcel D. Waldinger and Berend Olivier

Abstract

In human males, SSRIs differentially affect **(premature) ejaculation;** paroxetine and fluoxetine markedly and sertraline, moderately inhibited ejaculation latency, whereas fluvoxamine did not inhibit this parameter (Waldinger, M.D., Hengeveld, M.W., Zwinderman, A.H., Olivier, B., The effect of SSRI antidepressants on ejaculation: a double-blind, randomised, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J. Clin. Psychopharmacol. (in press)). The present studies tried to investigate, using sexual behaviour in male rats, whether such differences could also be found in animal paradigms of sexual behaviour. In a series of three experiments we compared various specific **serotonin** reuptake inhibitors (SSRIs) for their ability to suppress sexual behaviour in male rats. In the first experiment sexually experienced rats were tested 60 min after oral administration of clomipramine, fluvoxamine, fluoxetine (all in a range of 0, 3, 10 and 30 mg/kg p.o.), sertraline or paroxetine (both in a range of 0, 1, 3 and 10 mg/kg p.o.). Clomipramine, paroxetine and fluvoxamine did not significantly inhibit male sexual behaviour, although some trends were observed. Sertraline inhibited sexual behaviour at 3 and 10 mg/kg p.o., the effects being stronger at 3 mg/kg p.o. Fluoxetine (3 mg/kg p.o.) facilitated sexual behaviour, while at 30 mg/kg p.o. a modest increase in the postejaculatory interval was noted. In the second experiment, sexual behaviour of sexually naive male rats was slightly inhibited by paroxetine 10 mg/kg p.o., but sertraline (range 1–10 mg/kg p.o.), fluvoxamine and fluoxetine (both in a range of 3–30 mg/kg p.o.) were ineffective. In the last experiment the effects of paroxetine (0–10 mg/kg p.o.), fluvoxamine and fluoxetine (both 0–30 mg/kg p.o.) were studied during an exhaustion design in sexually experienced male rats. As rats get more 'sluggish' when they have had multiple ejaculations, we hoped to see stronger inhibitory effects in the last cycle prior to exhaustion. None of the drugs dose-dependently inhibited the pattern of sexual behaviour during the first sexual cycle. In the last cycle the patterning of sexual behaviour differed, but only paroxetine (10 mg/kg p.o.) inhibited sexual behaviour significantly. The total number of ejaculations during the test was not reduced by any of the SSRIs tested. Contrary to human findings, we did not find major inhibitory effects of SSRIs on male rat sexual behaviour at non-sedative doses. The only differentiation that could be made is that paroxetine and sertraline had slightly stronger effects than the other 5-HT reuptake inhibitors. Masculine sexual behaviour in rats does not constitute a suitable model to investigate the differential mechanism of sexual inhibition of SSRIs that have been described in human males.

---

10. ☒ **Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system** • **ARTICLE**

Behavioural Brain Research, Volume 92, Issue 2, May 1998, Pages 111-118
Marcel D. Waldinger, Hemmie H. G. Berendsen, Bertil F. M. Blok, Berend Olivier and Gert Holstege
SummaryPlus | Full Text + Links | PDF (278 K)

Premature ejaculation has generally been considered a psychosexual disorder with psychogenic aetiology. Although still mainly treated by behavioural therapy, in recent years double-blind studies have indicated the beneficial effects of some of the serotonergic antidepressants (SSRIs) in delaying ejaculation. We describe here the neurophysiology and the peripheral neuroanatomy of ejaculation and provide a review of the involvement of **serotonin** in the central nervous system in relation to serotonergic nuclei and their projections. A hypothesis of the role of 5-HT_{1A} and 5-HT_{2C} receptors in **premature ejaculation** is postulated.

---

11. **Fluoxetine treatment of comorbid premature ejaculation and panic disorder** • **ABSTRACT**
European Neuropsychopharmacology, Volume 6, Supplement 4, September 1996, Page S4
S. Kindler, O. T. Dolberg and M. Kotler
Abstract

---

12. **Sex behavior of male and female wistar rats affected by the serotonin agonist 8-OH-DPAT** • **ARTICLE**
Pharmacology Biochemistry and Behavior, Volume 40, Issue 2, October 1991, Pages 221-228
S. M. Haensel, J. Mos, B. Olivier and A. K. Slob
Abstract

Four experiments were carried out to test the stimulatory effects of 8-OH-DPAT on various aspects of "masculine" sexual behavior of male and female rats and on the sexual attractivity of male rats. In Experiment 1 8-OH-DPAT (0.2 mg/kg) stimulated ejaculation frequency in middle-aged (approx. 15 months old) males, both sexually inactive and active subjects. There was a coinciding decrease in total number of mounts, intromissions, intromissions to first ejaculation and latency to first ejaculation. In Experiment 2 the effects of two doses (0.2 and 0.4 mg/kg) 8-OH-DPAT on the first ejaculation cycle were investigated. Especially, the higher dose made a high percentage (45–55%) of males to ejaculate "prematurely," i.e., at the first or second intromission. Latency to ejaculation decreased. With the higher dose, 25–35% of the males ejaculated extravaginally. In Experiment 3 8-OH-DPAT did not make males more attractive for an estrous female than saline-treated males, as judged by the time spent in their vicinity. However, estrous females received much more ejaculations from the tethered 8-OH-DPAT males, with the lowest latencies to first ejaculation, than from the saline-treated males. In Experiment 4 8-OH-DPAT stimulated mounting behavior in female rats only when they were long-term treated with testosterone. In that condition also shortest latencies to first mount were found with 8-OH-DPAT treatment.

---

13. **Adult partner preference and sexual behavior of male rats affected by perinatal endocrine manipulations** • **ARTICLE**
Hormones and Behavior, Volume 25, Issue 3, September 1991, Pages 323-341
T. Brand, J. Kroonen, J. Mos and A. K. Slob
Abstract

Intact adult male rats, in which aromatization of testosterone to estradiol was prevented pre- and/or neonatally by ATD (1,4,6-androstatriene-3,17-dione), were repeatedly tested for partner preference behavior (choice: estrous female vs active male). In consecutive tests increasing preference scores for the female were found. Neonatal ATD males showed significantly lower preference scores for an estrous female than controls or prenatal ATD males. Prenatal ATD caused preference scores only slightly lower than those of controls. Ejaculation frequencies were markedly reduced or even absent in neonatal ATD males. Prenatal ATD treatment only had no or a moderately lowering effect on ejaculation frequency. Lordosis behavior of adult intact males was more facilitated following *neo*natal ATD treatment than following *pre*natal ATD treatment. In a number of tests the

serotonergic drug 8-OH-DPAT was injected prior to testing for sexual partner preference and copulatory behavior. DPAT significantly increased preference for an estrous female in all groups of males when interaction was possible, but had no effect when sexual interaction was prevented by wire mesh. DPAT was able to increase the number of ejaculators in nonejaculating groups (i.e., perinatally ATD-treated males). "**Premature ejaculations,**" i.e., ejaculations with the first intromission, were frequently observed with DPAT treatment in all groups of males. In conclusion, the availability of neonatal estrogen (derived from testosterone) organizes, at least partially, the preference for an estrous female normally shown by adult male rats. The lack of neonatal estrogen causes males to be less masculinized, both in partner preference behavior and ejaculatory behavior, and less defeminized in lordosis behavior. Treatment with a **serotonin** agonist (8-OH-DPAT) compensates, at least partially, the perinatal ATD effects on adult partner preference behavior and on ejaculatory behavior.

---

13 Articles Found

TITLE-ABSTR-KEY(sri or serotonin) and TITLE-ABSTR-KEY(premature ejaculation)

Edit Search | Save Search | Save as Search Alert

results **1 - 13**

10/723,478

C:\STNEXP4\QUERIES\~~10122608~~ (species).str





```
chain nodes :
    7  8  11  12
ring nodes :
    1  2  3  4  5  6  16  17  18  19  24  25  26  27  28  29
ring/chain nodes :
    9  13  14  15
chain bonds :
    3-7  8-9  11-14  11-15  12-13
ring bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-19  17-18  18-19  24-25  24-29  25-26  26-27  27-28
    28-29
exact/norm bonds :
    3-7  8-9  11-14  11-15  12-13  16-17  16-19  17-18  18-19
normalized bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  24-25  24-29  25-26  26-27  27-28  28-29
isolated ring systems :
    containing 1 : 16 : 24 :


G1:NH2,[*1],[*2],[*3]

Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  11:CLASS
    12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:Atom  18:Atom  19:Atom  24:CLASS
    25:CLASS  26:Atom  27:Atom  28:Atom  29:Atom  30:CLASS  31:CLASS
```

C:\STNEXP4\QUERIES\~~10122698~~ (Group I).str



chain nodes :
7 8 11 12 46
ring nodes :
1 2 3 4 5 6 16 17 18 19 24 25 26 27 28 29 30 31 32 38 39 40 41 42
43 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 72 73 74 75
76 77 78 79 80
ring/chain nodes :
9 13 14 15
chain bonds :
3-7 7-46 8-9 8-46 11-14 11-15 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-19 17-18 18-19 24-25 24-29 24-30 25-26 25-32
26-27 27-28 28-29 30-31 31-32 38-39 38-43 39-40 40-41 41-42 42-43 47-48 47-52
48-49 49-50 50-51 51-52 53-54 53-58 54-55 55-56 56-57 57-58 59-60 59-64 60-61
61-62 62-63 63-64 72-73 72-77 72-78 73-74 73-80 74-75 75-76 76-77 78-79 79-80
exact/norm bonds :
3-7 7-46 8-9 8-46 11-14 11-15 12-13 16-17 16-19 17-18 18-19 24-25 24-29 24-30
25-26 25-32 26-27 27-28 28-29 30-31 31-32 72-73 72-77 72-78 73-74 73-80 74-75
75-76 76-77 78-79 79-80
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 38-39 38-43 39-40 40-41 41-42 42-43 47-48 47-52 48-49
49-50 50-51 51-52 53-54 53-58 54-55 55-56 56-57 57-58 59-60 59-64 60-61 61-62
62-63 63-64
isolated ring systems :
containing 16 : 24 : 38 : 47 : 53 : 59 : 72 :

G1:NH2,[*1],[*2],[*3]

G3:[*4-*5],[*6-*7],[*8-*9],[*10-*11],[*12-*13],[*14-*15]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 24:Atom
25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS 38:Atom 39:Atom
40:Atom 41:Atom 42:Atom 43:Atom 46:CLASS 47:CLASS 48:Atom 49:Atom 50:Atom 51:Atom
52:Atom 53:Atom 54:Atom 55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom
62:Atom 63:Atom 64:Atom 72:Atom 73:CLASS 74:Atom 75:Atom 76:Atom 77:Atom 78:Atom
79:Atom 80:CLASS

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L1     SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2045 OR  2047

L2     SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10122698 (Group I).str

L3       STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1                SCR 1839
L2                SCR 2016 OR 2026 OR 2039 OR 2045 OR 2047
L3                STR
```




```
G1 NH2,[@1],[@2],[@3]


Structure attributes must be viewed using STN Express query preparation.
L4                QUE  L3 AND L1 NOT L2
```

```
=> s l4 sss sam
SAMPLE SEARCH INITIATED 16:13:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 204346 TO ITERATE

  0.5% PROCESSED    1000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS       0

L5            0 SEA SSS SAM L3 AND L1 NOT L2

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L6    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2045 OR  2047

L7    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10122698 (Group I).str

L8      STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9   QUE L8 AND L6 NOT L7

=> d l9
L9 HAS NO ANSWERS
L6              SCR 1839
L7              SCR 2016 OR 2026 OR 2039 OR 2045 OR 2047
L8              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L9              QUE  L8 AND L6 NOT L7


=> s l9 sss sam
SAMPLE SEARCH INITIATED 16:19:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   3953 TO ITERATE

 25.3% PROCESSED    1000 ITERATIONS                                14 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        75291 TO    82829
PROJECTED ANSWERS:             660 TO     1552

L10          14 SEA SSS SAM L8 AND L6 NOT L7

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L11   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2045 OR  2047

L12   SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10122698 (Group I).str

L13     STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14  QUE L13 AND L11 NOT L12

=> d l14
L14 HAS NO ANSWERS
L11             SCR 1839
L12             SCR 2016 OR 2026 OR 2039 OR 2045 OR 2047
L13             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L14             QUE  L13 AND L11 NOT L12


=> s l14 sss sam
SAMPLE SEARCH INITIATED 16:26:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    526 TO ITERATE

100.0% PROCESSED     526 ITERATIONS                                  4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       9145 TO    11895
PROJECTED ANSWERS:             4 TO      200

L15          4 SEA SSS SAM L13 AND L11 NOT L12

=> s l14 sss ful
FULL SEARCH INITIATED 16:27:24 FILE 'REGISTRY'
```

FULL SCREEN SEARCH COMPLETED - 10907 TO ITERATE

100.0% PROCESSED 10907 ITERATIONS 120 ANSWERS
SEARCH TIME: 00.00.01

L16 120 SEA SSS FUL L13 AND L11 NOT L12

=> s l16
L17 5 L16

=> d l17 1-5 bib,ab,hitstr

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2003:282325 CAPLUS
DN 138:321285
TI Preparation of quinazoline-2,4-diamines as MCH receptor antagonists
IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Tran, Thuy-anh; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 1171 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003028641	A2	20030410	WO 2002-US31059	20020930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-326463P P 20011001
US 2001-326758P P 20011002

AB The title compds. QLYR1[Q = I, C(:NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl), etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression, were prepd. Thus, hydrogenation of benzyl cis-[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexylmethyl]carbamate followed by reacting the resulting intermediate with 4-bromo-2-trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 34% cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.

IT **510745-97-8P 510746-93-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazoline-2,4-diamines as MCH receptor antagonists)

RN 510745-97-8 CAPLUS
CN 2,4-Quinazolinediamine, N4,N4-dimethyl-N2-[cis-4-[[[2-(4-methylphenoxy)-3-pyridinyl]methyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 510746-93-7 CAPLUS
CN 2,4-Quinazolinediamine, N4,N4-dimethyl-N2-[cis-4-[[[[2-(4-methylphenoxy)-3-pyridinyl]methyl]amino]methyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2002:814103 CAPLUS
DN 137:310821
TI Preparation of phenyl heterocyclyl ether derivatives as potent and selective inhibitors of serotonin re-uptake
IN Adam, Mavis Diane; Andrews, Mark David; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002083643	A1	20021024	WO 2002-IB1032	20020327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-9103 A 20010411
OS MARPAT 137:310821
AB Title compds. I [L, U = N, NO, CH; M, Q = N, NO, CR4; wherein ring A contains 1 or 2 N atoms, and L, U, M, Q = NO, ring A contains no other N atoms; R1, R2 = H, C1-6 alkyl, (CH2)m(C3-6 cycloalkyl); m = 0-3; NR1R2 = azetidine ring; W, Y, Z = H, halogen, C1-6 alkyl, CF3, OCF3, C1-4 alkylthio, C1-4 alkoxy; YZ = fused 5-7 membered (un)satd. arom. or carbocyclic or heterocyclic ring contg. 1-2 N, S and O in addn. to C atoms; W, Y, Z .noteq. H; R4 = AX; A = (CH2)p; p = 0-2; X = H, CONR6R7, SO2NR6R7, SO2NHCOR6, OH, C1-4 alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, SR10, SOR9, SO2R10; R6-8,R10 = H, C1-6 alkyl substituted by R12; R9 = C1-6 alkyl substituted by R12; R11 = H, C1-6 alkyl substituted by R12, COR6, CO2R9, CONHR6, SO2NR6R7; R12 = F, OH, CO2H, C3-6 cycloalkyl, NH2, CONH2, C1-6 alkoxy, C1-6 alkoxycarbonyl, 5-6 membered heterocyclic ring contg. 1-3 N, S, and O substituted by R13; NR6R7 = 4-6 membered heterocyclic ring and optionally substituted by R13; R13 = OH, C1-4 alkoxy, F, C1-6 alkyl, haloalkyl, haloalkoxy, (substituted) amino; M, Q = CR4; R4 groups form a fused 5-7 membered, (un)satd., arom. carbocyclic or heterocyclic ring] were prepd. For example, N-methyl-N-[[4-[4-(methylsulfanyl)phenoxy]-3-pyridinyl]methyl]amine bis(hydrochloride) (II) was prepd. in 68% yield from the com. available aldehyde III via reductive amination with 8M MeNH2 in EtOH in the presence of NaBH4. II had an serotonin re-uptake inhibition (SRI) IC50 .ltoreq. 25 nM, and it was 100-fold more potent in the inhibition of serotonin re-uptake than in the inhibition of dopamine re-uptake or noradrenaline re-uptake.
IT **473254-53-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of Ph heterocyclyl ether derivs. as potent and selective serotonin re-uptake inhibitors)
RN 473254-53-4 CAPLUS

CN 3-Pyridinemethanamine, 4-[(2,3-dihydrobenzo[b]thien-6-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 473254-26-1P 473254-27-2P 473254-29-4P
473254-31-8P 473254-33-0P 473254-34-1P
473254-35-2P 473254-36-3P 473254-37-4P
473254-38-5P 473254-39-6P 473254-40-9P
473254-41-0P 473254-42-1P 473254-43-2P
473254-44-3P 473254-46-5P 473254-47-6P
473254-48-7P 473254-49-8P 473254-50-1P
473254-51-2P 473254-52-3P 473254-54-5P
473254-55-6P 473254-56-7P 473254-57-8P
473254-58-9P 473254-59-0P 473254-60-3P
473254-61-4P 473254-62-5P 473254-63-6P
473254-64-7P 473254-65-8P 473254-66-9P
473254-67-0P 473254-68-1P 473254-69-2P
473254-70-5P 473254-71-6P 473254-72-7P
473254-73-8P 473254-74-9P 473254-75-0P
473254-76-1P 473254-77-2P 473254-78-3P
473254-79-4P 473254-80-7P 473254-81-8P
473254-82-9P 473254-83-0P 473254-84-1P
473254-85-2P 473254-86-3P 473254-87-4P
473254-88-5P 473254-89-6P 473254-90-9P
473254-91-0P 473254-92-1P 473254-93-2P
473254-94-3P 473254-95-4P 473254-96-5P
473254-97-6P 473254-98-7P 473254-99-8P
473255-00-4P 473255-01-5P 473255-02-6P
473255-03-7P 473255-04-8P 473255-05-9P
473255-06-0P 473255-07-1P 473255-08-2P
473255-09-3P 473255-10-6P 473255-11-7P
473255-12-8P 473255-13-9P 473255-14-0P
473255-15-1P 473255-16-2P 473255-18-4P
473255-20-8P 473255-22-0P 473255-24-2P
473255-26-4P 473255-27-5P 473255-28-6P
473255-30-0P 473255-31-1P 473255-32-2P
473255-34-4P 473255-37-7P 473255-38-8P
473255-39-9P 473255-40-2P 473255-41-3P
473255-42-4P 473255-43-5P 473255-44-6P
473255-47-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Ph heterocyclyl ether derivs. as potent and selective serotonin re-uptake inhibitors)

RN 473254-26-1 CAPLUS

CN 4-Pyridinemethanamine, 3-[3-methoxy-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-27-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydro-1,4-benzoxathiin-6-yl)oxy]- (9CI) (CA INDEX NAME)



RN 473254-29-4 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-31-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)





RN 473254-33-0 CAPLUS
CN 2-Pyridinemethanamine, 3-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-34-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-fluoro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-35-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(methylthio)-3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-36-3 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-methyl-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-37-4 CAPLUS
CN 4-Pyridinemethanamine, 3-(4-ethylphenoxy)- (9CI) (CA INDEX NAME)





RN 473254-38-5 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydro-1H-inden-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 473254-39-6 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydrobenzo[b]thien-6-yl)oxy]- (9CI) (CA INDEX NAME)



RN 473254-40-9 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-ethyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-41-0 CAPLUS
CN 4-Pyridinemethanamine, 3-[(1,3-dihydrobenzo[c]thien-5-yl)oxy]- (9CI) (CA INDEX NAME)



RN 473254-42-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(ethylthio)phenoxy]- (9CI) (CA INDEX NAME)





RN 473254-43-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-chloro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-44-3 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-chloro-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-46-5 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-47-6 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-48-7 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-49-8 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydrobenzo[b]thien-5-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-50-1 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-chloro-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 473254-51-2 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-7-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 473254-52-3 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-54-5 CAPLUS
CN 3-Pyridinemethanamine, 4-(4-ethylphenoxy)-N-methyl- (9CI) (CA INDEX NAME)





RN 473254-55-6 CAPLUS
CN 3-Pyridinemethanamine, 4-[(1,3-dihydrobenzo[c]thien-5-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-56-7 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-5-methyl-1,4-benzoxathiin-7-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-57-8 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-5-methyl-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-58-9 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-6-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 473254-59-0 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-ethyl-3-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-60-3 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-ethyl-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-61-4 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-62-5 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methoxy-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-63-6 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-64-7 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-65-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydro-1H-inden-5-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-66-9 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-67-0 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-68-1 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[4-methyl-3-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-69-2 CAPLUS
CN 4-Pyridinemethanamine, 3-(4-ethylphenoxy)-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-70-5 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydrobenzo[b]thien-6-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-71-6 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-ethyl-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-72-7 CAPLUS
CN 4-Pyridinemethanamine, 3-[(1,3-dihydrobenzo[c]thien-5-yl)oxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-73-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(ethylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-74-9 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-chloro-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-75-0 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-chloro-3-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-76-1 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-7-yl)oxy]-N,6-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-77-2 CAPLUS
CN 3-Pyridinemethanamine, N,6-dimethyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-78-3 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-4-(methylthio)phenoxy]-N,6-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-79-4 CAPLUS
CN 3-Pyridinemethanamine, N,6-dimethyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-80-7 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-6-yl)oxy]-N,6-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-81-8 CAPLUS
CN 3-Pyridinemethanamine, 6-methyl-4-[4-methyl-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-82-9 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-6-methyl- (9CI) (CA INDEX NAME)



RN 473254-83-0 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N,6-dimethyl- (9CI) (CA INDEX NAME)





RN 473254-84-1 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-85-2 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-86-3 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydrobenzo[b]thien-6-yl)oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 473254-87-4 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-chloro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-88-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-7-yl)oxy]-N,N,6-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-89-6 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-fluoro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-90-9 CAPLUS
CN 3-Pyridinemethanamine, N,N,6-trimethyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-91-0 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-7-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-92-1 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-93-2 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydrobenzo[b]thien-5-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-94-3 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-fluoro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-95-4 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-96-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-6-yl)oxy]-N,N,6-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-97-6 CAPLUS
CN 2-Pyridinemethanamine, N,N-dimethyl-3-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-98-7 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydro-1,4-benzoxathiin-6-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-99-8 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-00-4 CAPLUS
CN 3-Pyridinemethanamine, N,N,6-trimethyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-01-5 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-02-6 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[4-methyl-3-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-03-7 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-5-methyl-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-04-8 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-5-methyl-1,4-benzoxathiin-7-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-05-9 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methoxy-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-06-0 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydro-1,4-benzoxathiin-6-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-07-1 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-ethyl-3-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-08-2 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-ethyl-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-09-3 CAPLUS
CN 3-Pyridinemethanamine, 4-[(2,3-dihydrobenzo[b]thien-6-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-10-6 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-11-7 CAPLUS
CN 4-Pyridinemethanamine, 3-[(2,3-dihydrobenzo[b]thien-6-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-12-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-ethyl-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-13-9 CAPLUS
CN 4-Pyridinemethanamine, 3-[(1,3-dihydrobenzo[c]thien-5-yl)oxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-14-0 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(ethylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-15-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-chloro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-16-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-chloro-3-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-18-4 CAPLUS
CN 3-Pyridinemethanamine, N,N,6-trimethyl-4-[4-methyl-3-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-20-8 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N,N,6-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-22-0 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-24-2 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-26-4 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(methylthio)phenoxy]-, 1-oxide, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-27-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-28-6 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-30-0 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)





RN 473255-31-1 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-32-2 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-34-4 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-(6-quinolinyloxy)- (9CI) (CA INDEX NAME)



RN 473255-37-7 CAPLUS
CN Pyridine, 3-(1-azetidinylmethyl)-4-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473255-38-8 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[4-(methylthio)phenoxy]-, 1-oxide, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-39-9 CAPLUS
CN 3-Pyridinemethanamine, 4-(3,4-dichlorophenoxy)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-40-2 CAPLUS
CN 3-Quinolinemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-41-3 CAPLUS
CN 3-Pyridinemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-42-4 CAPLUS
CN 3-Pyridinemethanamine, 2-(4-chlorophenoxy)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-43-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(dimethylamino)methyl]-6-[4-(trifluoromethoxy)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 473255-44-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-[(dimethylamino)methyl]-6-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 473255-47-9 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[3-methyl-4-(methylthio)phenoxy]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 473255-46-8
CMF C15 H18 N2 O S



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT **473255-45-7P 473255-48-0P 473255-49-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of Ph heterocyclyl ether derivs. as potent and selective serotonin re-uptake inhibitors)
RN 473255-45-7 CAPLUS
CN Formamide, N-[[3-[3-methoxy-4-(methylthio)phenoxy]-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 473255-48-0 CAPLUS
CN 3-Pyridinemethanamine, 5-bromo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 473255-49-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(dimethylamino)methyl]-6-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2002:487497 CAPLUS
DN 137:78952
TI Preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators
IN Thurkauf, Andrew; Zhang, Xiaoyan; He, Xia-Shu; Zhao, He; Peterson, John; Maynard, George; Ohliger, Robert
PA Neurogen Corporation, USA
SO PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002049993	A2	20020627	WO 2000-US26816	20000929
WO 2002049993	A3	20030220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000076225	A5	20020701	AU 2000-76225	20000929
PRAI WO 2000-US26816	W	20000929		

OS MARPAT 137:78952
AB The invention includes low mol. wt., non-peptidic, non-peptidommetic, org. mols. that can act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also such ligands that can act as antagonists or inverse agonists of complement C5a receptors. Preferred compds. of the invention possess some or all of the following properties in that they are: (1) multi-aryl in structure; (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose can provide a detectable in vivo effect; (4) comprise fewer than four or preferably no amide bonds, and (5) capable of habiting leukocyte chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include imidazoles I [R1 = H, OH, halo, etc.; R2 = alkyl, cycloalkyl, etc.; R3 H, alkyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.], pyrazoles II [R = H, OH, halo, etc.; R2, R3 = H, OH, halo, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.], amides Ar1CONR1R2 [III; R1, R2 = alkyl, alkenyl, cycloalkyl, etc.; Ar1 = (un)substituted carbocyclic aryl, arylalkyl, etc.], etc. Detailed prepn. of some compds. I-III was given. E.g., a multi-step synthesis of I [Ar1 = Ph; R1, R3 = H; R2 = Bu; R4, Ar2 = 3,4-methylenedioxyphenyl] was presented. The invention also includes pharmaceutical compn. comprising such compds. I-III and the use of such compds. in treating a variety of inflammatory and immune system disorders.
IT **439570-38-4P 439570-39-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)
RN 439570-38-4 CAPLUS

CN 3-Pyridinemethanamine, N-(1,3-benzodioxol-5-ylmethyl)-N-[[1-butyl-2-(4-fluorophenyl)-1H-imidazol-5-yl]methyl]-6-methyl-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 439570-39-5 CAPLUS

CN 3-Pyridinemethanamine, N-(1,3-benzodioxol-5-ylmethyl)-N-[[1-butyl-2-(4-fluorophenyl)-1H-imidazol-5-yl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L17 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:545665 CAPLUS
DN 135:137515
TI Preparation of pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones as corticotropin releasing factor antagonists
IN Chen, Yuhpyng Liang
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053263	A1	20010726	WO 2001-IB4	20010105
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2001007662	A	20021119	BR 2001-7662	20010105
	EP 1263732	A1	20021211	EP 2001-900209	20010105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002016328	A1	20020207	US 2001-761995	20010117
	BG 106853	A	20030131	BG 2002-106853	20020620
	NO 2002003424	A	20020910	NO 2002-3424	20020717
PRAI	US 2000-176611P	P	20000118		
	WO 2001-IB4	W	20010105		

OS MARPAT 135:137515
AB The title compds. [I-III; A = CR7, N; B = NR1R2, COR2, CHR1OR2, etc.; G = H, O, S, etc.; Y = CH, N; Z = NH, O, S, etc.; R1 = CHO, CO(alkyl), alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = Me, Et, F, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 = (un)substituted (hetero)aryl; R6 = H, alkyl, cycloalkyl, etc.; R16, R17 = H, OH, Me, etc.], useful in the treatment disorders including CNS and stress-related disorders, were prepd. Thus, reacting N-4-(1-ethylpropyl)-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3,4-diamine with chloroacetyl chloride in the presence of Et3N in THF afforded 91% I [A = CH; B = NHCHEt2; R3 = Me; R4 = NHCOCH2Cl; Z = O; R5 = 2,4,6-Me3C6H2]. The CRF binding activities for compds. I-III, expressed as IC50 values, generally range from about 0.5 nM to 10 .mu.M.
IT **203244-37-5P 351380-66-0P 351380-67-1P**
351380-68-2P 351382-56-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones as corticotropin releasing factor antagonists)
RN 203244-37-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[(1-ethylpropyl)amino]-6-methyl-2-(2,4,6-trimethylphenoxy)- (9CI) (CA INDEX NAME)



RN 351380-66-0 CAPLUS
CN 3-Pyridinemethanamine, 2-(4-chloro-2,6-dimethylphenoxy)-4-[[(1S)-1-(chloromethyl)propyl]amino]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351380-67-1 CAPLUS
CN 1-Butanol, 2-[[2-(4-chloro-2,6-dimethylphenoxy)-6-methyl-3-[(methylamino)methyl]-4-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351380-68-2 CAPLUS
CN 1-Butanol, 2-[[3-(aminomethyl)-2-(4-chloro-2,6-dimethylphenoxy)-6-methyl-4-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351382-56-4 CAPLUS
CN 3-Pyridinemethanamine, 2-(4-chloro-2,6-dimethylphenoxy)-N,6-dimethyl-4-[(tetrahydro-3-furanyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1998:112362 CAPLUS
DN 128:180424
TI Preparation of substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives as CRF antagonists
IN Chen, Yuhpyng Liang
PA Pfizer Inc., USA; Chen, Yuhpyng Liang
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9805661	A1	19980212	WO 1997-IB918	19970723
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9733563	A1	19980225	AU 1997-33563	19970723
	AU 709203	B2	19990826		
	EP 920429	A1	19990609	EP 1997-929472	19970723
	EP 920429	B1	20030219		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9710808	A	19990817	BR 1997-10808	19970723
	CN 1227552	A	19990901	CN 1997-197079	19970723
	CN 1093130	B	20021023		
	JP 2000501116	T2	20000202	JP 1998-507754	19970723
	JP 3345021	B2	20021118		
	CA 2262692	C	20020611	CA 1997-2262692	19970723
	AT 232863	E	20030315	AT 1997-929472	19970723
	AP 1096	A	20020826	AP 1997-1052	19970731
	W: BW, GM, KE, MW, UG, ZM, ZW				
	NO 9900544	A	19990331	NO 1999-544	19990205
	US 6492520	B1	20021210	US 1999-242076	19990524
PRAI	US 1996-23453P	P	19960806		
	WO 1997-IB918	W	19970723		

OS MARPAT 128:180424
AB The title compds. [I; A = N, CR7; B = NR1R2, COR2, CR1R2R10, etc., and is single bonded to D; B = CR1R2, and is double bonded to D and D is carbon; D = N, CR4 and is single bonded to all atoms to which it is attached, or D = C and is double bonded to E or double bonded to B; E = O, N, S, etc.; K, G = C(O), C(S), S, etc.; 6-7 membered ring that contains D, E, K and G may contain 1-3 double bonds, 0-2 heteroatoms selected from O, N and S, and 0-2 C(O) or C(S); R1 = (un)substituted C1-6 alkyl; R2 = (un)substituted C1-12 alkyl, aryl, (C1-4 alkylene)aryl, etc.; R3 = H, C1-4 alkyl, halo, etc.; R5 = Ph, naphthyl, pyridyl, etc.; R7 = H, Me, halo, etc.; R10 = H, OH, MeO, F], useful as corticotropin releasing factor (hormone) CRF (CRH) antagonists, were prepd. Thus, treatment of 2-chloro-N-[4-(1-ethylpropylamino)-6-methyl-2-(2,4,6-trimethylphenoxy)pyridin-3-yl]acetamide (prepn. described) with lithium bis(trimethylsilyl)amide in THF afforded 59% the title compd. II. Compds. I are effective at 0.1-50 mg/kg/day.

IT **203244-37-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of substituted pyrido- or pyrimido-contg. 6,6- or 6,7-bicyclic derivs. as CRF antagonists)
RN 203244-37-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[(1-ethylpropyl)amino]-6-methyl-2-(2,4,6-trimethylphenoxy)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 16:12:51 ON 22 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 16:12:56 ON 22 MAY 2003
L1               SCREEN 1839
L2               SCREEN 2016 OR  2026 OR  2039 OR  2045 OR  2047
L3               STRUCTURE UPLOADED
L4               QUE L3 AND L1 NOT L2
L5             0 S L4 SSS SAM
L6               SCREEN 1839
L7               SCREEN 2016 OR  2026 OR  2039 OR  2045 OR  2047
L8               STRUCTURE UPLOADED
L9               QUE L8 AND L6 NOT L7
L10           14 S L9 SSS SAM
L11              SCREEN 1839
L12              SCREEN 2016 OR  2026 OR  2039 OR  2045 OR  2047
L13              STRUCTURE UPLOADED
L14              QUE L13 AND L11 NOT L12
L15            4 S L14 SSS SAM
L16          120 S L14 SSS FUL

     FILE 'CAPLUS' ENTERED AT 16:27:31 ON 22 MAY 2003
L17            5 S L16

     FILE 'CAOLD' ENTERED AT 16:28:14 ON 22 MAY 2003

=> s l16
L18            0 L16

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.40     181.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.26

STN INTERNATIONAL LOGOFF AT 16:28:25 ON 22 MAY 2003
```

```
=>
Uploading 10122698 (species).str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:06:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 184276 TO ITERATE

  0.5% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS       0

L2            0 SEA SSS SAM L1

=>
Uploading 10122698 (species).str

L3      STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam
SAMPLE SEARCH INITIATED 14:09:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 208945 TO ITERATE

  0.5% PROCESSED    1000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS       0

L4            0 SEA SSS SAM L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2026 OR  2039 OR  2016 OR  2045

L5    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10122698 (species).str

L6      STRUCTURE UPLOADED

=> que L6 NOT L5

L7   QUE L6 NOT L5

=> d his

     (FILE 'HOME' ENTERED AT 14:06:23 ON 01 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 14:06:28 ON 01 MAY 2003
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3              STRUCTURE UPLOADED
L4            0 S L3 SSS SAM
L5              SCREEN 2026 OR  2039 OR  2016 OR  2045
L6              STRUCTURE UPLOADED
L7              QUE L6 NOT L5

=> s l7 sss sam
SAMPLE SEARCH INITIATED 14:13:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  39940 TO ITERATE

  2.5% PROCESSED    1000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      786909 TO   810691
PROJECTED ANSWERS:              0 TO        0

L8            0 SEA SSS SAM L6 NOT L5

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end
```

```
=> screen 2026 OR  2039 OR  2016 OR  2045

L9    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10122698 (species).str

L10     STRUCTURE UPLOADED

=> que L10 NOT L9

L11  QUE L10 NOT L9

=> d l11
L11 HAS NO ANSWERS
L9              SCR 2026 OR 2039 OR 2016 OR 2045
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L11             QUE  L10 NOT L9


=> s l11 sss sam
SAMPLE SEARCH INITIATED 14:21:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  18945 TO ITERATE

  5.3% PROCESSED    1000 ITERATIONS                                  1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       370674 TO   387126
PROJECTED ANSWERS:             117 TO      639

L12           1 SEA SSS SAM L10 NOT L9

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2026 OR  2039 OR  2016 OR  2045

L13   SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10122698 (species).str

L14     STRUCTURE UPLOADED

=> que L14 NOT L13

L15  QUE L14 NOT L13
```

```
=> d l15
L15 HAS NO ANSWERS
L13             SCR 2026 OR 2039 OR 2016 OR 2045
L14             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L15             QUE  L14 NOT L13


=> s l15 sss sam
SAMPLE SEARCH INITIATED 14:24:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  18945 TO ITERATE

  5.3% PROCESSED    1000 ITERATIONS                                  1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       370674 TO   387126
PROJECTED ANSWERS:             117 TO      639

L16           1 SEA SSS SAM L14 NOT L13

=> s l15 sss ful
FULL SEARCH INITIATED 14:24:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 378186 TO ITERATE

100.0% PROCESSED  378186 ITERATIONS                              280 ANSWERS
SEARCH TIME: 00.00.04

L17         280 SEA SSS FUL L14 NOT L13

=> s l17
L18          24 L17

=> d l18 1-24 bib,ab,hitstr
```

L18 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2003:5948 CAPLUS
DN 138:55963
TI Preparation of pyrazolyloxypyridines as herbicides and plant growth regulators
IN Haaf, Klaus; Willms, Lothar; Auler, Thomas; Menne, Hubert; Bieringer, Hermann
PA Bayer Cropscience Gmbh, Germany
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003000679	A2	20030103	WO 2002-EP6840	20020620
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SG, SI, SK, TJ, TM, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10130397	A1	20030109	DE 2001-10130397	20010623
PRAI DE 2001-10130397	A	20010623		

OS MARPAT 138:55963
AB Title compds. [I; R1 = H, halo, cyano, NO2, SF5, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkylcarbonyl, alkylsulfonyl, SOpR7, C(:W)OR10; p = 0-2; R7 = alkyl, haloalkyl, NR8R9; R8,R9 = H, (substituted) alkyl, alkenyl, arylalkyl, alkylaryl, aryl; R10 = (substituted) alkyl; W = O, S; A = (substituted) aryl, heterocyclic group; X = O, S; R2-5 = H, halo, cyano, (substituted) alkoxy, alkyl; m = 0, 1; R6 = H, (substituted) alkyl, alkoxy, alkenyl, alkynyl, OH, acyl; B = acyl; or BR6 = 4-5 membered chain] and salts thereof were prepd. Thus, 2-(1-methyl-3-trifluoromethylpyrazol-5-yloxy)-6-(aminomethyl)pyridine (prepn. given) in HCO2Et was refluxed for 3 h to give 91% 2-(1-methyl-3-trifluoromethylpyrazol-5-yloxy)-6-(formylaminomethyl)pyridine. Several I were said to show very good pre- and postemergent herbicidal activity and very good crop tolerance.
IT **479626-25-0P 479626-76-1P 479626-77-2P**
479626-78-3P 479626-79-4P 479626-80-7P
479626-81-8P 479626-82-9P 479626-83-0P
479626-84-1P 479626-86-3P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (pyrazolyloxy)pyridines as herbicides and plant growth regulators)
RN 479626-25-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-76-1 CAPLUS
CN Benzamide, 4-chloro-3-nitro-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-77-2 CAPLUS
CN Benzamide, 2,4,6-trifluoro-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-78-3 CAPLUS
CN 2-Butenamide, 3-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-79-4 CAPLUS
CN Acetamide, 2-chloro-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-80-7 CAPLUS
CN Propanamide, 2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-81-8 CAPLUS
CN Propanamide, 2-fluoro-2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-82-9 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-83-0 CAPLUS
CN Cyclopropanecarboxamide, N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-84-1 CAPLUS
CN Cyclobutanecarboxamide, N-[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 479626-86-3 CAPLUS
CN Acetic acid, oxo[[[6-[3-(trifluoromethyl)phenoxy]-2-pyridinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **479626-24-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (pyrazolyloxy)pyridines as herbicides and plant growth regulators)
RN 479626-24-9 CAPLUS
CN 2-Pyridinemethanamine, 6-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2002:814103 CAPLUS
DN 137:310821
TI Preparation of phenyl heterocyclyl ether derivatives as potent and selective inhibitors of serotonin re-uptake
IN Adam, Mavis Diane; Andrews, Mark David; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002083643	A1	20021024	WO 2002-IB1032	20020327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2001-9103 A 20010411 ← Appl. Foreign Priority Doc.
OS MARPAT 137:310821
AB Title compds. I [L, U = N, NO, CH; M, Q = N, NO, CR4; wherein ring A contains 1 or 2 N atoms, and L, U, M, Q = NO, ring A contains no other N atoms; R1, R2 = H, C1-6 alkyl, (CH2)m(C3-6 cycloalkyl); m = 0-3; NR1R2 = azetidine ring; W, Y, Z = H, halogen, C1-6 alkyl, CF3, OCF3, C1-4 alkylthio, C1-4 alkoxy; YZ = fused 5-7 membered (un)satd. arom. or carbocyclic or heterocyclic ring contg. 1-2 N, S and O in addn. to C atoms; W, Y, Z .noteq. H; R4 = AX; A = (CH2)p; p = 0-2; X = H, CONR6R7, SO2NR6R7, SO2NHCOR6, OH, C1-4 alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, SR10, SOR9, SO2R10; R6-8,R10 = H, C1-6 alkyl substituted by R12; R9 = C1-6 alkyl substituted by R12; R11 = H, C1-6 alkyl substituted by R12, COR6, CO2R9, CONHR6, SO2NR6R7; R12 = F, OH, CO2H, C3-6 cycloalkyl, NH2, CONH2, C1-6 alkoxy, C1-6 alkoxycarbonyl, 5-6 membered heterocyclic ring contg. 1-3 N, S, and O substituted by R13; NR6R7 = 4-6 membered heterocyclic ring and optionally substituted by R13; R13 = OH, C1-4 alkoxy, F, C1-6 alkyl, haloalkyl, haloalkoxy, (substituted) amino; M, Q = CR4; R4 groups form a fused 5-7 membered, (un)satd., arom. carbocyclic or heterocyclic ring] were prepd. For example, N-methyl-N-[[4-[4-(methylsulfanyl)phenoxy]-3-pyridinyl]methyl]amine bis(hydrochloride) (II) was prepd. in 68% yield from the com. available aldehyde III via reductive amination with 8M MeNH2 in EtOH in the presence of NaBH4. II had an serotonin re-uptake inhibition (SRI) IC50 .ltoreq. 25 nM, and it was 100-fold more potent in the inhibition of serotonin re-uptake than in the inhibition of dopamine re-uptake or noradrenaline re-uptake.
IT **473254-26-1P 473254-29-4P 473254-31-8P**
473254-33-0P 473254-34-1P 473254-35-2P
473254-36-3P 473254-37-4P 473254-40-9P
473254-42-1P 473254-43-2P 473254-44-3P
473254-46-5P 473254-47-6P 473254-48-7P
473254-50-1P 473254-52-3P 473254-54-5P
473254-57-8P 473254-59-0P 473254-60-3P

473254-61-4P 473254-62-5P 473254-63-6P
473254-64-7P 473254-66-9P 473254-67-0P
473254-68-1P 473254-69-2P 473254-71-6P
473254-73-8P 473254-74-9P 473254-75-0P
473254-77-2P 473254-78-3P 473254-79-4P
473254-81-8P 473254-82-9P 473254-83-0P
473254-84-1P 473254-85-2P 473254-87-4P
473254-89-6P 473254-90-9P 473254-92-1P
473254-94-3P 473254-95-4P 473254-97-6P
473254-99-8P 473255-00-4P 473255-01-5P
473255-02-6P 473255-03-7P 473255-05-9P
473255-07-1P 473255-08-2P 473255-10-6P
473255-12-8P 473255-14-0P 473255-15-1P
473255-16-2P 473255-18-4P 473255-20-8P
473255-22-0P 473255-24-2P 473255-26-4P
473255-27-5P 473255-28-6P 473255-30-0P
473255-31-1P 473255-32-2P 473255-37-7P
473255-38-8P 473255-39-9P 473255-41-3P
473255-42-4P 473255-43-5P 473255-44-6P
473255-47-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Ph heterocyclyl ether derivs. as potent and selective serotonin re-uptake inhibitors)

RN 473254-26-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methoxy-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-29-4 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



Elected spec.

RN 473254-31-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)





RN 473254-33-0 CAPLUS
CN 2-Pyridinemethanamine, 3-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-34-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-fluoro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-35-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(methylthio)-3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-36-3 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-methyl-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-37-4 CAPLUS
CN 4-Pyridinemethanamine, 3-(4-ethylphenoxy)- (9CI) (CA INDEX NAME)





RN 473254-40-9 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-ethyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-42-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(ethylthio)phenoxy]- (9CI) (CA INDEX NAME)





RN 473254-43-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-chloro-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-44-3 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-chloro-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-46-5 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-47-6 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-48-7 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-50-1 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-chloro-4-(methylthio)phenoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 473254-52-3 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-54-5 CAPLUS
CN 3-Pyridinemethanamine, 4-(4-ethylphenoxy)-N-methyl- (9CI) (CA INDEX NAME)





RN 473254-57-8 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-5-methyl-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-59-0 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-ethyl-3-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-60-3 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-ethyl-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-61-4 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-62-5 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methoxy-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-63-6 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-64-7 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-fluoro-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-66-9 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-67-0 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-68-1 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[4-methyl-3-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-69-2 CAPLUS
CN 4-Pyridinemethanamine, 3-(4-ethylphenoxy)-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-71-6 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-ethyl-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-73-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(ethylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-74-9 CAPLUS

CN 4-Pyridinemethanamine, 3-[3-chloro-4-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-75-0 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-chloro-3-(methylthio)phenoxy]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-77-2 CAPLUS
CN 3-Pyridinemethanamine, N,6-dimethyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-78-3 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-4-(methylthio)phenoxy]-N,6-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-79-4 CAPLUS
CN 3-Pyridinemethanamine, N,6-dimethyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-81-8 CAPLUS
CN 3-Pyridinemethanamine, 6-methyl-4-[4-methyl-3-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-82-9 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-6-methyl- (9CI) (CA INDEX NAME)



RN 473254-83-0 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N,6-dimethyl- (9CI) (CA INDEX NAME)





RN 473254-84-1 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-2-[4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-85-2 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-2-[3-methyl-4-(methylthio)phenoxy]- (9CI) (CA INDEX NAME)



RN 473254-87-4 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-chloro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-89-6 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-fluoro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-90-9 CAPLUS
CN 3-Pyridinemethanamine, N,N,6-trimethyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473254-92-1 CAPLUS

CN 4-Pyridinemethanamine, N,N-dimethyl-3-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-94-3 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-fluoro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-95-4 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-97-6 CAPLUS
CN 2-Pyridinemethanamine, N,N-dimethyl-3-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473254-99-8 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-00-4 CAPLUS
CN 3-Pyridinemethanamine, N,N,6-trimethyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-01-5 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[4-(methylthio)-3-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-02-6 CAPLUS
CN 4-Pyridinemethanamine, N,N-dimethyl-3-[4-methyl-3-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-03-7 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-5-methyl-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-05-9 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-methoxy-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-07-1 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-ethyl-3-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-08-2 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-ethyl-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-10-6 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-12-8 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-ethyl-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-14-0 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-(ethylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-15-1 CAPLUS
CN 4-Pyridinemethanamine, 3-[3-chloro-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-16-2 CAPLUS
CN 4-Pyridinemethanamine, 3-[4-chloro-3-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-18-4 CAPLUS
CN 3-Pyridinemethanamine, N,N,6-trimethyl-4-[4-methyl-3-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-20-8 CAPLUS
CN 3-Pyridinemethanamine, 4-[4-chloro-3-(methylthio)phenoxy]-N,N,6-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-22-0 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-2-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-24-2 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-2-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-26-4 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(methylthio)phenoxy]-, 1-oxide, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-27-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[3-methoxy-4-(methylthio)phenoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-28-6 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-30-0 CAPLUS

CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)





RN 473255-31-1 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-32-2 CAPLUS
CN 3-Pyridinemethanamine, N,N-dimethyl-4-[3-methyl-4-(methylthio)phenoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 473255-37-7 CAPLUS
CN Pyridine, 3-(1-azetidinylmethyl)-4-[4-(methylthio)phenoxy]- (9CI) (CA

INDEX NAME)



RN 473255-38-8 CAPLUS
CN 3-Pyridinemethanamine, N-methyl-4-[4-(methylthio)phenoxy]-, 1-oxide, dihydrochloride (9CI) (CA INDEX NAME)





●2 HCl

RN 473255-39-9 CAPLUS
CN 3-Pyridinemethanamine, 4-(3,4-dichlorophenoxy)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-41-3 CAPLUS
CN 3-Pyridinemethanamine, 2-(3,4-dichlorophenoxy)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-42-4 CAPLUS
CN 3-Pyridinemethanamine, 2-(4-chlorophenoxy)-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473255-43-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(dimethylamino)methyl]-6-[4-(trifluoromethoxy)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 473255-44-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-[(dimethylamino)methyl]-6-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 473255-47-9 CAPLUS
CN 4-Pyridinemethanamine, N-methyl-3-[3-methyl-4-(methylthio)phenoxy]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 473255-46-8
CMF C15 H18 N2 O S



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT **473255-45-7P 473255-48-0P 473255-49-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of Ph heterocyclyl ether derivs. as potent and selective serotonin re-uptake inhibitors)
RN 473255-45-7 CAPLUS
CN Formamide, N-[[3-[3-methoxy-4-(methylthio)phenoxy]-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 473255-48-0 CAPLUS
CN 3-Pyridinemethanamine, 5-bromo-N,N-dimethyl-2-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 473255-49-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(dimethylamino)methyl]-6-[4-(trifluoromethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2002:487497 CAPLUS
DN 137:78952
TI Preparation of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators
IN Thurkauf, Andrew; Zhang, Xiaoyan; He, Xia-Shu; Zhao, He; Peterson, John; Maynard, George; Ohliger, Robert
PA Neurogen Corporation, USA
SO PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049993	A2	20020627	WO 2000-US26816	20000929
	WO 2002049993	A3	20030220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2000076225	A5	20020701	AU 2000-76225	20000929
PRAI	WO 2000-US26816	W	20000929	-	

OS MARPAT 137:78952
AB The invention includes low mol. wt., non-peptidic, non-peptidommetic, org. mols. that can act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also such ligands that can act as antagonists or inverse agonists of complement C5a receptors. Preferred compds. of the invention possess some or all of the following properties in that they are: (1) multi-aryl in structure; (2) heteroaryl in structure; (3) a pharmaceutically acceptable oral dose can provide a detectable in vivo effect; (4) comprise fewer than four or preferably no amide bonds, and (5) capable of habiting leukocyte chemotaxis at nanomolar or sub-nanomolar concns. Such compds. include imidazoles I [R1 = H, OH, halo, etc.; R2 = alkyl, cycloalkyl, etc.; R3 H, alkyl, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.], pyrazoles II [R = H, OH, halo, etc.; R2, R3 = H, OH, halo, etc.; R4 = alkyl, alkenyl, cycloalkyl, etc.; Ar1, Ar2 = (un)substituted carbocyclic aryl, arylalkyl, etc.], amides Ar1CONR1R2 [III; R1, R2 = alkyl, alkenyl, cycloalkyl, etc.; Ar1 = (un)substituted carbocyclic aryl, arylalkyl, etc.], etc. Detailed prepn. of some compds. I-III was given. E.g., a multi-step synthesis of I [Ar1 = Ph; R1, R3 = H; R2 = Bu; R4, Ar2 = 3,4-methylenedioxyphenyl] was presented. The invention also includes pharmaceutical compn. comprising such compds. I-III and the use of such compds. in treating a variety of inflammatory and immune system disorders.
IT **439570-38-4P 439570-39-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted imidazoles, pyrazoles and amides as high affinity C5a receptor modulators)
RN 439570-38-4 CAPLUS

CN 3-Pyridinemethanamine, N-(1,3-benzodioxol-5-ylmethyl)-N-[[1-butyl-2-(4-fluorophenyl)-1H-imidazol-5-yl]methyl]-6-methyl-2-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 439570-39-5 CAPLUS

CN 3-Pyridinemethanamine, N-(1,3-benzodioxol-5-ylmethyl)-N-[[1-butyl-2-(4-fluorophenyl)-1H-imidazol-5-yl]methyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2002:220560 CAPLUS
DN 136:263098
TI Preparation of pyridinyl amides and imides for use as fungicides
IN Neubert, Timothy Donald; Piotrowski, David Walter; Walker, Michael Paul
PA E. I. Du Pont De Nemours and Company, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022583	A2	20020321	WO 2001-US28971	20010917
	WO 2002022583	A3	20020718		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002011233	A5	20020326	AU 2002-11233	20010917
PRAI	US 2000-233374P	P	20000918		
	US 2001-277199P	P	20010320		
	WO 2001-US28971	W	20010917		

OS MARPAT 136:263098
AB Title compds. [ACRR1R2YWB; A is a substituted pyridinyl ring; B is a substituted pyridinyl ring; W is C:L, SOn; L = O, S, CXR4; R1 and R2 are each independently = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, each optionally substituted; Y = NR3; R3 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylaminocarbonyl, C3-C8 dialkylaminocarbonyl; R4 = C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, each optionally substituted; X = O, S; n = 1, 2; provided that when W is CO and R1, R2 and R3 are H; then B is other than 4-trifluoromethyl-3-pyridinyl, 2-chloro-4-pyridinyl and 2,6-dihalo-4-pyridinyl], N-oxides and agriculturally suitable salts are prepd. and disclosed which are useful as fungicides. Also disclosed are compns. contg. the compds. I and a method for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amt. of a compd. I.
IT **404875-86-1P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of pyridinyl amides and imides for use as fungicides)
RN 404875-86-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)


O
N
C
NH
CH2
N
O
Me
CF3

L18 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2002:220534 CAPLUS
DN 136:263165
TI Preparation of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indanecarboxamides, thiochromancarboxamide, and chromancarboxamide derivatives as C5a receptor antagonists and medicinal use thereof
IN Nakamura, Mitsuharu; Kamahori, Takao; Ishibuchi, Seigo; Naka, Yoichi; Sumichika, Hiroshi; Itoh, Katsuhiko
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 415 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022556	A1	20020321	WO 2001-JP7977	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088045	A5	20020326	AU 2001-88045	20010914
PRAI JP 2000-280540	A	20000914		
JP 2000-386813	A	20001220		
WO 2001-JP7977	W	20010914		

OS MARPAT 136:263165
AB Amide derivs. represented by the following general formula [I; R1, R2, R3, R4 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, or alkoxy, aryloxy, arylalkyloxy, (un)substituted acyloxy, halo, NO2, cyano, acyl SH, alkylthio, alkylsulfinyl, NH2, alkylamino, dialkylamino, cyclic amino, (un)substituted CONH2, alkoxycarbonyl, CO2h, acylamino, (un)substituted SO2NH2, haloalkyl; or any two of R1, R2, and R3 together with adjacent carbon atom form a ring; all a, b, c, d, and e is a carbon atom; or one or two of a, b, c, d, and e represent one or two nitrogen atom and the other represent C atoms; R4, R5, R6 = haloalkyloxy, groups listed in R1 - R4; A = H, (un)substituted cycloalkyl, aryl, heteroaryl, or cyclic amino; W1, W2 = a bond, (un)substituted C1-3 alkylene; Y = a single bond, O, CO, NR7, S, SO, SO2, CONR8, NR9CO (wherein R7, R8, R9 = H, (un)substituted alkyl); Z = a single bond, (un)substituted alkylene] or optically active isomers thereof or pharmaceutically acceptable salts thereof are prepd. These compds. are useful as preventives and remedies for diseases or syndromes caused by inflammation induced by C5a, e.g. immunol. diseases such as rheumatism and systemic lupus erythematosus, allergic diseases such as sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease and asthma, atherosclerosis, heart infarction, brain infarction, psoriasis, Alzheimer's disease and important organistic breakdown (e.g. pneumonia, nephritis, hepatitis, pancreatitis) induced by leukocyte activation caused by ischemic reperfusion, burn or surgical invasion. Moreover, they are useful as preventives and remedies for infection with bacteria and viruses mediated by C5a receptor. Thus, to a soln. of 3.3 g 1,2,3,4-tetrahydronaphthalene-1-carboxylic acid in 20 mL CH2Cl2 was added

2.1 mL SO2Cl2 and the resulting mixt. was refluxed for 3 h, concd. under reduced pressure, dissolved in 10 mL CH2Cl2, treated with a soln. of 5.1 g N-[(4-dimethylaminophenyl)methyl](4-isopropylphenyl)amine in 10 mL CH2Cl2 under ice-cooling, warmed to room temp., and stirred overnight to give N-[(4-dimethylaminophenyl)methyl]-N-(4-isopropylphenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide (II). II inhibited the binding of [125I]-human C5a receptor to human histiocystic lymphoma cell line (U-937) with IC50 of 104 nm/mL. A tablet, a capsule, an injection soln., and an eyedrop formulation contg. II were prepd.

IT **405103-41-5**, (4-Isopropylphenyl)[(6-phenoxypyridin-3-yl)methyl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 1,2,3,4-tetrahydronaphthalenecarboxamide, 1,2,3,4-tetrahydroquinolinecarboxamide, indancarboxamides, thiochromancarboxamide, and chromancarboxamide derivs. as C5a receptor antagonists and medicinal use thereof)

RN 405103-41-5 CAPLUS

CN 3-Pyridinemethanamine, N-[4-(1-methylethyl)phenyl]-6-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2002:183754 CAPLUS
DN 136:226804
TI Combination, for treating depression and anxiety, containing a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist
IN Schmidt, Christopher Joseph; Sobolov-Jaynes, Susan Beth
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1186318	A2	20020313	EP 2001-307220	20010824
	EP 1186318	A3	20030326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2002049211	A1	20020425	US 2001-867357	20010529
	JP 2002121153	A2	20020423	JP 2001-264226	20010831
	BR 2001003913	A	20020521	BR 2001-3913	20010906
PRAI	US 2000-230257P	P	20000906		

OS MARPAT 136:226804
AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compns. contg. a pharmaceutically-acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT1D receptor antagonist.
IT **368832-01-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination, for treating depression and anxiety, contg. a 5HT1D receptor antagonist and a CNS penetrant NK-1 receptor antagonist)
RN 368832-01-3 CAPLUS
CN 4-Pyridinemethanamine, 3-chloro-2-(4-fluorophenoxy)-N-[(2R,3R)-2-phenyl-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2001:762988 CAPLUS
DN 135:331346
TI Synthesis of benzoamide piperidine containing compounds as substance P antagonists
IN Arnold, Eric Platt; Chappie, Thomas Allen; Huang, Jianhua; Humphrey, John Michael; Nagel, Arthur Adam; O'Neill, Brian Thomas; Sobolov-Jaynes, Susan Beth; Vincent, Lawrence Albert
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 209 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077100	A2	20011018	WO 2001-IB629	20010406
	WO 2001077100	A3	20020307		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1272484	A2	20030108	EP 2001-919702	20010406
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2002004874	A	20021118	NO 2002-4874	20021009
PRAI	US 2000-195922P	P	20000410		
	US 2000-212922P	P	20000620		
	WO 2001-IB629	W	20010406		

OS MARPAT 135:331346
AB Title compds. I [Q = C:NH, C:CH2, C:S, C:O, SO, SO2; A = CH, CH2, C(alkyl), CH(alkyl), C(CF3), or CH(CF3) with the proviso that when B is present, A = CH, C(alkyl), or C(CF3); B = absent, CH2, or ethylene; Y, Z = N, CH, provided that both are not N; G = NH(CH2)q, S(CH2)q, O(CH2)q; q = 0-1 with the proviso that when q = 0, G = NH2, SH, OH; W = 1-3 carbon linking group, including spiro assemblies; p = 0-2; R3 = H, acyl, carboxy, Ph, heterocyclyl, alkyl, etc.; R1, R2, R11-13 = H, alkyl, etc., or R12-13 together with the carbon atoms to which they are attached form a 5- or 6-membered heterocyclic ring, etc.; R4 = Ph, pyridyl, thienyl, etc.; R5-8 = H, alkyl, S(O)1-2-alkyl, S(O)1-2-aryl, alkoxy, halo, Ph, etc.] were prepd. Approx. 100 synthetic examples and over 100 precursor prepns. were provided. For instance, 4-aminophenol was acylated with 3-chloropropionyl chloride (CH2Cl2, H2O, NaHCO3, room temp., 4 h) and the product treated with AlCl3 at 210.degree.C for 10 min effecting cyclization to the hydroxy quinolone intermediate. The intermediate was O-methylated (acetone, Me2SO4, K2CO3, room temp., 16 h) and formylated in the 7 position (CH2Cl2, AlCl3, Cl2CHOMe) to give 7-formyl-6-methoxy-1H-1,2,3,4-tetrahydroquinolin-2-one. Reductive alkylation of the quinolone with (2S,3S)-3-amino-2-phenylpiperidine (a. PhMe, 3.ANG. mol. sieves; b. dichloroethane, NaHB(OAc)3, room temp., 16 h) yielded II. Compds. I are NK-1 receptor antagonists, i.e., substance P receptor antagonists. At least one stereoisomer of the example compds. had a binding affinity, as measured by Ki, of at least 600 nM. I are used in the treatment and prevention of a

wide variety of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, etc.

IT **368832-01-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; synthesis of benzoamide piperidine contg. compds. as substance P antagonists)

RN 368832-01-3 CAPLUS

CN 4-Pyridinemethanamine, 3-chloro-2-(4-fluorophenoxy)-N-[(2R,3R)-2-phenyl-3-piperidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2001:545665 CAPLUS
DN 135:137515
TI Preparation of pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones as corticotropin releasing factor antagonists
IN Chen, Yuhpyng Liang
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053263	A1	20010726	WO 2001-IB4	20010105
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2001007662	A	20021119	BR 2001-7662	20010105
	EP 1263732	A1	20021211	EP 2001-900209	20010105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002016328	A1	20020207	US 2001-761995	20010117
	BG 106853	A	20030131	BG 2002-106853	20020620
	NO 2002003424	A	20020910	NO 2002-3424	20020717
PRAI	US 2000-176611P	P	20000118		
	WO 2001-IB4	W	20010105		

OS MARPAT 135:137515
AB The title compds. [I-III; A = CR7, N; B = NR1R2, COR2, CHR1OR2, etc.; G = H, O, S, etc.; Y = CH, N; Z = NH, O, S, etc.; R1 = CHO, CO(alkyl), alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = Me, Et, F, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 = (un)substituted (hetero)aryl; R6 = H, alkyl, cycloalkyl, etc.; R16, R17 = H, OH, Me, etc.], useful in the treatment disorders including CNS and stress-related disorders, were prepd. Thus, reacting N-4-(1-ethylpropyl)-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3,4-diamine with chloroacetyl chloride in the presence of Et3N in THF afforded 91% I [A = CH; B = NHCHEt2; R3 = Me; R4 = NHCOCH2Cl; Z = O; R5 = 2,4,6-Me3C6H2]. The CRF binding activities for compds. I-III, expressed as IC50 values, generally range from about 0.5 nM to 10 .mu.M.
IT **203244-37-5P 351380-66-0P 351380-67-1P 351380-68-2P 351382-56-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones as corticotropin releasing factor antagonists)
RN 203244-37-5 CAPLUS
CN 3-Pyridinemethanamine, 4-[(1-ethylpropyl)amino]-6-methyl-2-(2,4,6-trimethylphenoxy)- (9CI) (CA INDEX NAME)



2 Differences.

RN 351380-66-0 CAPLUS
CN 3-Pyridinemethanamine, 2-(4-chloro-2,6-dimethylphenoxy)-4-[[(1S)-1-(chloromethyl)propyl]amino]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351380-67-1 CAPLUS
CN 1-Butanol, 2-[[2-(4-chloro-2,6-dimethylphenoxy)-6-methyl-3-[(methylamino)methyl]-4-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351380-68-2 CAPLUS
CN 1-Butanol, 2-[[3-(aminomethyl)-2-(4-chloro-2,6-dimethylphenoxy)-6-methyl-4-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 351382-56-4 CAPLUS
CN 3-Pyridinemethanamine, 2-(4-chloro-2,6-dimethylphenoxy)-N,6-dimethyl-4-[(tetrahydro-3-furanyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2001:531966 CAPLUS
DN 135:122498
TI Preparation of pyrazole-5-carboxamides and their use for insecticides and acaricides
IN Okada, Itaru; Ikeda, Yoshiya; Shiga, Yasushi; Fukuchi, Toshiki
PA Mitsubishi Chemical Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001199984	A2	20010724	JP 2000-14367	20000124
PRAI JP 2000-14367		20000124		

OS MARPAT 135:122498
AB Pyrazole-5-carboxamides I [R1 = alkyl; R2 = H, alkyl; R3, R4 = H, cyano, alkylthio, (halo)alkyl, NO2, etc.] are prepd. Thus, N-acylation of 3-tert-butyl-1-methyl-N-[6-(4-methylthiophenoxy)pyridin-3-ylmethyl]pyrazole-5-carboxamide with isobutyryl chloride gave I (R1 = CMe3, R2 = CHMe2, R3 = SMe, R4 = H), which at 500 ppm showed 100% acaricidal activity.
IT **350792-99-3P 350793-00-9P 350793-01-0P**
350793-02-1P 350793-03-2P 350793-04-3P
350793-05-4P 350793-06-5P 350793-07-6P
350793-08-7P 350793-09-8P 350793-10-1P
350793-11-2P 350793-12-3P 350793-13-4P
350793-14-5P 350793-15-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole-5-carboxamides as insecticides and acaricides)
RN 350792-99-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-00-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-1-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 350793-01-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-(1,1-dimethylethyl)-1-methyl-N-(2-methyl-1-oxopropyl)-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-02-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-1-methyl-N-[[6-[4-(methylthio)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-03-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-3-(1,1-dimethylethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 350793-04-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-1-methyl-N-[[6-[4-(methylsulfinyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-05-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-1-methyl-N-[[6-[4-(methylsulfonyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-06-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-N-[[6-(4-fluorophenoxy)-3-pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 350793-07-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-3-(1,1-dimethylethyl)-1-methyl-N-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 350793-08-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-(1,1-dimethylethyl)-1-methyl-N-(2-methyl-1-oxopropyl)-N-[[6-[4-(methylthio)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-09-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-(1,1-dimethylethyl)-1-methyl-N-(2-methyl-1-oxopropyl)-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-10-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-(1,1-dimethylethyl)-N-[[6-(4-fluorophenoxy)-3-pyridinyl]methyl]-1-methyl-N-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 350793-11-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-(1,1-dimethylethyl)-1-methyl-N-[[6-[4-(phenylethynyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-12-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-ethyl-1-methyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-13-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-1-methyl-N-(2-methyl-1-oxopropyl)-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 350793-14-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-3-ethyl-N-[[6-(4-iodophenoxy)-3-pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 350793-15-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-N-[[6-(4-cyanophenoxy)-3-pyridinyl]methyl]-3-ethyl-1-methyl- (9CI) (CA INDEX NAME)



IT **350793-16-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazole-5-carboxamides as insecticides and acaricides)
RN 350793-16-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-(1,1-dimethylethyl)-1-methyl-N-[[6-[4-(methylthio)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2000:393273 CAPLUS
DN 133:177446
TI New macrobicyclic receptors for amino acids
AU Jullian, Valerie; Shepherd, Emma; Gelbrich, Thomas; Hursthouse, Michael B.; Kilburn, Jeremy D.
CS Department of Chemistry, University of Southampton, Southampton, SO17 1BJ, UK
SO Tetrahedron Letters (2000), 41(20), 3963-3966
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 133:177446
AB Two new receptors, I (X = N, Y = O, W = (CH2)3NHCSNH(CH2)3; X = CH, Y = CH2), were prepd., utilizing a pyridyl aryl ether unit in the rim of the macrobicyclic structure, and the crystal structures for both of these receptors are reported. The presence of the pyridyl unit provides addnl. H-bonding functionality in comparison to earlier structures of this type, and I (X = N, Y = O) is an effective receptor for N-acetyl-L-asparagine carboxylate in CH2Cl2.
IT **288588-40-9P 288588-42-1P 288588-44-3P**
288588-49-8P 288588-54-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of macrobicyclic receptors for amino acids)
RN 288588-40-9 CAPLUS
CN Benzoic acid, 4-[[5-(aminomethyl)-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 288588-42-1 CAPLUS
CN Benzoic acid, 4-[[5-[[[(2S)-6-amino-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxohexyl]amino]methyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288588-44-3 CAPLUS

CN 2,8,10,16-Tetraazaheptadecanedioic acid, 3,15-bis[[[[6-[4-(methoxycarbonyl)phenoxy]-3-pyridinyl]methyl]amino]carbonyl]-9-thioxo-, bis(1,1-dimethylethyl) ester, (3S,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 288588-49-8 CAPLUS

CN Benzoic acid, 4-[[5-[[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-6-isothiocyanato-1-oxohexyl]amino]methyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288588-54-5 CAPLUS

CN 2,8,10,16-Tetraazaheptadecanedioic acid, 3-[[[[6-[4-(methoxycarbonyl)phenoxy]-3-pyridinyl]methyl]amino]carbonyl]-15-[[[[4-[[4-(methoxycarbonyl)phenyl]methyl]phenyl]methyl]amino]carbonyl]-9-thioxo-, bis(1,1-dimethylethyl) ester, (3S,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1999:595144 CAPLUS
DN 131:214287
TI Preparation of pyrazolecarboxamides as insecticides, acaricides, and fungicides
IN Kano, Hiroki; Ikeda, Yoshiya; Kyomura, Nobuo; Tomita, Hirofumi; Fukuchi, Toshiki
PA Mitsubishi Chemical Corporation, Japan
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9946247	A1	19990916	WO 1999-JP1160	19990310
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2002187882	A2	20020705	JP 1998-59510	19980311
	AU 9927470	A1	19990927	AU 1999-27470	19990310
PRAI	JP 1998-59510	A	19980311		
	WO 1999-JP1160	W	19990310		

OS MARPAT 131:214287
AB Title compds. I [R1, R2 = H, alkyl; R3 = H, halo, alkyl, etc.; R4 = H, alkyl, acyl, alkoxycarbonyl, alkoxyalkyl; R5, R6 = H, alkyl; A = (un)substituted Ph, 5- or 6-membered heterocyclyl; Y = a group contg. C=C, C.tplbond.C], useful as insecticides, acaricides, and fungicides, were prepd. Thus, chlorination of 4-ethynyl-1,3-dimethylpyrazole-5-carboxylic acid with SOCl2 followed by amidation with 2-(2-naphthoxy)-5-aminomethylpyridine gave 15% 4-ethynyl-1,3-dimethyl-N-[2-(2-naphthoxy)pyridin-5-ylmethyl]pyrazole-5-carboxamide (II). II showed fungicidal activity against Puccinia recondita at 250 ppm.
IT **243465-87-4P 243465-89-6P 243466-02-6P**
243466-03-7P 243466-05-9P 243466-09-3P
243466-19-5P 243466-20-8P 243466-21-9P
243466-22-0P 243466-23-1P 243466-24-2P
243466-25-3P 243466-26-4P 243466-27-5P
243466-28-6P 243466-29-7P 243466-30-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazolecarboxamides as insecticides, acaricides, and fungicides)
RN 243465-87-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-ethynyl-1,3-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243465-89-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-ethynyl-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243466-02-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243466-03-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-3-ethyl-4-ethynyl-1-methyl- (9CI) (CA INDEX NAME)



RN 243466-05-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-

(3-methoxy-1-propynyl)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 243466-09-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-ethenyl-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243466-19-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-ethynyl-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 243466-20-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-bromophenoxy)-3-pyridinyl]methyl]-4-ethynyl-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 243466-21-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-ethynyl-N-[[6-(4-methoxyphenoxy)-3-pyridinyl]methyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 243466-22-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-1-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 243466-23-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-1-methyl-N-[[6-(4-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243466-24-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-N-[[6-(4-methoxyphenoxy)-3-pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 243466-25-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-1-methyl-N-[[6-[4-(methylthio)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243466-26-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-N-[[6-(4-fluorophenoxy)-3-pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 243466-27-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-bromophenoxy)-3-pyridinyl]methyl]-3-ethyl-4-ethynyl-1-methyl- (9CI) (CA INDEX NAME)



RN 243466-28-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-N-[[6-(4-ethynylphenoxy)-3-

pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 243466-29-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-N-[[6-[4-[(methoxyimino)methyl]phenoxy]-3-pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 243466-30-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-ethynyl-1-methyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



IT **197459-39-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazolecarboxamides as insecticides, acaricides, and fungicides)
RN 197459-39-5 CAPLUS
CN 3-Pyridinemethanamine, 6-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1999:355718 CAPLUS
DN 131:18832
TI Preparation of substituted 2-aminoacetamides as sodium channel blockers
IN Lan, Nancy C.; Wang, Yan; Cai, Sui Xiong
PA Cocensys, Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926614	A1	19990603	WO 1998-US24965	19981120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2310664	AA	19990603	CA 1998-2310664	19981120
	AU 9914215	A1	19990615	AU 1999-14215	19981120
	AU 749214	B2	20020620		
	EP 1032377	A1	20000906	EP 1998-958114	19981120
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL, IE				
	JP 2001523710	T2	20011127	JP 2000-521816	19981120
	US 6479484	B1	20021112	US 2000-554739	20000808
	US 2002016464	A1	20020207	US 2001-933203	20010821
	US 6500825	B2	20021231		
PRAI	US 1997-66707P	P	19971121		
	WO 1998-US24965	W	19981120		
	US 2000-554739	A3	20000808		

OS MARPAT 131:18832
AB The title compds. [I; R1-R4 = H, alkyl, cycloalkyl, etc.; R5-R7 = H, alkyl, alkenyl, etc.; A1, A2 = (un)substituted aryl, heteroaryl, (un)satd. carbocycle, etc.; X = O, S, CH2, etc.; n = 0-3], useful for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy, were prepd. E.g., reaction of 4-(3,4-methylenedioxyphenoxy)benzaldehyde with 2-amino-2,2-dimethylethanamide (prepn. of both reagents is given) in the presence of 3.ANG. mol. sieves in EtOH followed by treatment of the resulting mixt. with NaBH3CN afforded 11% II. Biol. data for compds. I were given.
IT **226708-64-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted 2-aminoacetamides as sodium channel blockers)
RN 226708-64-1 CAPLUS
CN Propanamide, 2-[[[5-(4-fluorophenoxy)-3-pyridinyl]methyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1999:64676 CAPLUS
DN 130:110643
TI Preparation and formulation of amino acid derivatives as N calcium channel inhibitors
IN Seko, Takuya; Kato, Masashi
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 358 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902146	A1	19990121	WO 1998-JP3013	19980703
	W: AU, CA, CN, HU, JP, KR, MX, NO, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9879372	A1	19990208	AU 1998-79372	19980703
	EP 997147	A1	20000503	EP 1998-929830	19980703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	ZA 9805940	A	19990119	ZA 1998-5940	19980706
	US 2003013725	A1	20030116	US 2002-154780	20020528
PRAI	JP 1997-197784	A	19970708		
	JP 1998-148405	A	19980513		
	WO 1998-JP3013	W	19980703		
	US 2000-462447	A1	20000107		

OS MARPAT 130:110643
AB The title compds. R1AN(R2)CH(DER3)COJR4 [R1 represents optionally substituted alkyl, alkoxy or Ph, a heterocyclic group, etc.; A represents a single bond, CO or SO2; R2 represents H, optionally substituted alkyl, etc.; D represents alkylene, etc.; E represents COO, OCO, O, S, SO, SO2, etc.; R3 represents optionally substituted alkyl, a carbocyclic group or a heterocycle group; J represents O or NR16 (wherein R16 represents H or optionally substituted alkyl); and R4 represents optionally substituted alkyl, a carbocyclic group or a heterocyclic group] are prepd. I are useful as preventives and/or remedies for cerebral infarction, transient cerebral ischemic attack, cerebrospinal disorders following heart operations, spinal vascular lesion, stress hypertension, neurosis, epilepsy, etc. or remedies for pains. In an in vitro test, the title compd. I at 3 .mu.M gave 87% inhibition of calcium influx.
IT **219625-16-8P 219626-02-5P 219626-70-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as N calcium channel inhibitors)
RN 219625-16-8 CAPLUS
CN Carbamic acid, [(1R)-1-[[(cyclohexylmethyl)thio]methyl]-2-oxo-2-[[(6-phenoxy-3-pyridinyl)methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219626-02-5 CAPLUS
CN 3-Thiazolidinecarboxylic acid, 4-[[[(1R)-1-[[(cyclohexylmethyl)thio]methyl]-2-oxo-2-[[(6-phenoxy-3-pyridinyl)methyl]amino]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219626-70-7 CAPLUS
CN 4-Thiazolidinecarboxamide, N-[(1R)-1-[[(cyclohexylmethyl)thio]methyl]-2-oxo-2-[[(6-phenoxy-3-pyridinyl)methyl]amino]ethyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1998:126656 CAPLUS
DN 128:180411
TI Preparation of pyrazoles, and agrochemical microbicides, insecticides, and acaricides containing them
IN Okimura, Nobuo; Ikeda, Yoshiya; Okui, Kaneko; Tomita, Hirofumi; Azumano, Sumiaki
PA Mitsubishi Chemical Industries Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10053583	A2	19980224	JP 1996-211378	19960809
PRAI JP 1996-211378		19960809		

OS MARPAT 128:180411
AB Pyrazoles I [R1, R2 = OH, C1-4 (halo)alkoxy, AcO, C1-4 alkoxyalkoxy, benzyloxy, etc.; R = (un)substituted Ph with C1-4 (halo)alkyl, C1-4 haloalkoxy, etc.] are prepd. 4-Methoxy-1,3-dimethyl-5-pyrazolecarboxylic acid was refluxed with SOCl2, and reacted with 5-aminomethyl-2-(4-trifluoromethylphenoxy)pyridine in the presence of Et3N to give I (R1 = Me, R2 = OMe, R3 = H, R = C6H4CF3-4) (II). II at 500 ppm exhibited 100% insecticidal activity.
IT **203246-01-9P 203246-02-0P 203246-03-1P**
203246-05-3P 203246-06-4P 203246-08-6P
203246-10-0P 203246-12-2P 203246-14-4P
203246-16-6P 203246-18-8P 203246-20-2P
203246-22-4P 203246-23-5P 203246-25-7P
203246-26-8P 203246-27-9P 203246-28-0P
203246-29-1P 203246-30-4P 203246-32-6P
203246-34-8P 203246-36-0P 203246-38-2P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazoles as agrochem. microbicides, insecticides, and acaricides)
RN 203246-01-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-hydroxy-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-02-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-hydroxy-1,3-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-03-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-[4-(difluoromethyl)phenoxy]-3-pyridinyl]methyl]-4-hydroxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 203246-05-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-methoxy-1,3-dimethyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 203246-06-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-methoxy-1,3-dimethyl-N-[[6-(4-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-08-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-methoxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 203246-10-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-methoxy-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-12-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-methoxy-1,3-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-14-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-[3-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-4-methoxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 203246-16-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[[6-[4-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-4-methoxy-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 203246-18-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-ethoxy-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-20-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1,3-dimethyl-4-propoxy-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-22-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1,3-dimethyl-4-(phenylmethoxy)-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-23-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1,3-dimethyl-4-(phenylmethoxy)-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-25-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-[4-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-1,3-dimethyl-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 203246-26-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-(difluoromethoxy)-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-27-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-(difluoromethoxy)-1,3-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-28-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-(difluoromethoxy)-N-[[6-[4-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 203246-29-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-(methoxymethoxy)-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-30-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-(acetyloxy)-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-32-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 3-ethyl-4-methoxy-1-methyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-34-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-methoxy-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-36-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-3-methoxy-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203246-38-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-acetyl-4-methoxy-1,3-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



IT **203246-41-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazoles as agrochem. microbicides, insecticides, and acaricides)
RN 203246-41-7 CAPLUS
CN 3-Pyridinemethanamine, 6-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1998:112362 CAPLUS
DN 128:180424
TI Preparation of substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives as CRF antagonists
IN Chen, Yuhpyng Liang
PA Pfizer Inc., USA; Chen, Yuhpyng Liang
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9805661	A1	19980212	WO 1997-IB918	19970723
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9733563	A1	19980225	AU 1997-33563	19970723
	AU 709203	B2	19990826		
	EP 920429	A1	19990609	EP 1997-929472	19970723
	EP 920429	B1	20030219		
	-R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9710808	A	19990817	BR 1997-10808	19970723
	CN 1227552	A	19990901	CN 1997-197079	19970723
	CN 1093130	B	20021023		
	JP 2000501116	T2	20000202	JP 1998-507754	19970723
	JP 3345021	B2	20021118		
	AT 232863	E	20030315	AT 1997-929472	19970723
	AP 1096	A	20020826	AP 1997-1052	19970731
	W: BW, GM, KE, MW, UG, ZM, ZW				
	NO 9900544	A	19990331	NO 1999-544	19990205
	US 6492520	B1	20021210	US 1999-242076	19990524
PRAI	US 1996-23453P	P	19960806		
	WO 1997-IB918	W	19970723		

OS MARPAT 128:180424
AB The title compds. [I; A = N, CR7; B = NR1R2, COR2, CR1R2R10, etc., and is single bonded to D; B = CR1R2, and is double bonded to D and D is carbon; D = N, CR4 and is single bonded to all atoms to which it is attached, or D = C and is double bonded to E or double bonded to B; E = O, N, S, etc.; K, G = C(O), C(S), S, etc.; 6-7 membered ring that contains D, E, K and G may contain 1-3 double bonds, 0-2 heteroatoms selected from O, N and S, and 0-2 C(O) or C(S); R1 = (un)substituted C1-6 alkyl; R2 = (un)substituted C1-12 alkyl, aryl, (C1-4 alkylene)aryl, etc.; R3 = H, C1-4 alkyl, halo, etc.; R5 = Ph, naphthyl, pyridyl, etc.; R7 = H, Me, halo, etc.; R10 = H, OH, MeO, F], useful as corticotropin releasing factor (hormone) CRF (CRH) antagonists, were prepd. Thus, treatment of 2-chloro-N-[4-(1-ethylpropylamino)-6-methyl-2-(2,4,6-trimethylphenoxy)pyridin-3-yl]acetamide (prepn. described) with lithium bis(trimethylsilyl)amide in THF afforded 59% the title compd. II. Compds. I are effective at 0.1-50 mg/kg/day.
IT **203244-37-5**

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of substituted pyrido- or pyrimido-contg. 6,6- or 6,7-bicyclic derivs. as CRF antagonists)

RN 203244-37-5 CAPLUS

CN 3-Pyridinemethanamine, 4-[(1-ethylpropyl)amino]-6-methyl-2-(2,4,6-trimethylphenoxy)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1997:684402 CAPLUS
DN 127:307382
TI Preparation of pyrazole derivatives as agrochemical fungicides, insecticides, and acaricides
IN Kyomura, Nobuo; Ikeda, Yoshiya; Okui, Shuko; Tomita, Hirofumi; Higashino, Yoshiaki; Koike, Sanae
PA Mitsubishi Chemical Corp., Japan; Kyomura, Nobuo; Ikeda, Yoshiya; Okui, Shuko; Tomita, Hirofumi; Higashino, Yoshiaki; Koike, Sanae
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9737990	A1	19971016	WO 1997-JP1162	19970404
	W: AU, CN, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 09278775	A2	19971028	JP 1996-83587	19960405
	JP 10053582	A2	19980224	JP 1996-211377	19960809
	AU 9721785	A1	19971029	AU 1997-21785	19970404
	EP 891975	A1	19990120	EP 1997-914601	19970404
	R: DE, DK, ES, FR, GB, IT, NL, PT, IE				
PRAI	JP 1996-83587		19960405		
	JP 1996-211377		19960809		
	WO 1997-JP1162		19970404		

OS MARPAT 127:307382
AB The title compds. I [R1 is H, alkyl, haloalkyl, alkoxy or phenyl; R2 is H, halogeno, hydroxyl, alkyl, alkoxy, haloalkoxy, alkoxyalkoxy or benzyloxy, or alternatively R1 and R2 may be united to form Q; R4 is H or alkyl; R3 is H, alkyl, alkenyl, cycloalkenyl, alkoxyalkyl, benzyloxyalkyl, formyl, alkanoyl, benzoyl, alkoxycarbonyl, benzyloxycarbonyl, alkylsulfonyl or arylsulfonyl; and R is (un)substituted naphthalenyl (generic structure given), etc.] are prepd. I are superior to known agricultural chems. in activity and are extremely safe. The title compd. II at 250 ppm gave total prevention of Magnaporthe grisea infection in rice plants.
IT **197458-59-6P 197458-60-9P 197458-61-0P**
197458-62-1P 197458-63-2P 197458-64-3P
197458-65-4P 197458-66-5P 197458-67-6P
197458-68-7P 197458-69-8P 197458-70-1P
197458-71-2P 197458-72-3P 197458-73-4P
197458-74-5P 197458-76-7P 197458-77-8P
197458-78-9P 197458-79-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole derivs. as agrochem. fungicides, insecticides, and acaricides)
RN 197458-59-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-60-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-61-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-62-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-63-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-bromo-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-64-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-iodo-1,3-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-65-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1,3,4-trimethyl-N-[[6-(3-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-66-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(3-chlorophenoxy)-3-pyridinyl]methyl]-1,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 197458-67-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[[6-(3-bromophenoxy)-3-pyridinyl]methyl]-1,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 197458-68-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1,3,4-trimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-69-8 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-[3-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-1,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 197458-70-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-71-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-3-ethyl-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-72-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-bromo-3-ethyl-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-73-4 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-ethyl-1,4-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-74-5 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-1-methyl-3-(1-methylethyl)-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-76-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 3-cyclohexyl-1-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-77-8 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-78-9 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-2,6-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 197458-79-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-methyl-3-(trifluoromethyl)-N-[[6-[3-

(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



IT **197459-39-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as agrochem. fungicides, insecticides, and acaricides)
RN 197459-39-5 CAPLUS
CN 3-Pyridinemethanamine, 6-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1996:673442 CAPLUS
DN 126:8201
TI Organic phosphorus compounds. 106. A 31P-NMR study of phosphinous, phosphinic, and thiophosphinic amides
AU Maier, Ludwig; Diel, Peter J.
CS Agricultural Division, CIBA-GEIGY AG, Basel, CH-4002, Switz.
SO Phosphorus, Sulfur and Silicon and the Related Elements (1996), 115, 273-300
CODEN: PSSLEC; ISSN: 1042-6507
PB Gordon & Breach
DT Journal
LA English
AB The synthesis, phys., chem. and spectroscopic properties of eight different types of phosphinous, phosphinic and thiophosphinic amides, e.g., (ClCH2)PhP(O)NPr2, are reported. The 31P-chem. shifts of tertiary amides are at lower magnetic field than that of secondary amides. As an exception, in the bis(tert-butyl) series this trend is reversed.
IT **183798-26-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and 31P-NMR study of phosphinous, phosphinic, and thiophosphinic amides)
RN 183798-26-7 CAPLUS
CN 2-Pyridinemethanamine, 6-phenoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1996:560561 CAPLUS
DN 125:195645
TI Preparation of (pyridylmethylaminocarbonyl)indazoles as fungicides, insecticides and miticides.
IN Kyomura, Nobuo; Okui, Shuko; Ikeda, Yoshiya; Suzuki, Shigeru; Tomita, Hirofumi; Higashino, Yoshiaki
PA Mitsubishi Chemical Corporation, Japan
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 726266	A1	19960814	EP 1996-101596	19960205
	EP 726266	B1	19980107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT				
	JP 08277287	A2	19961022	JP 1996-4963	19960116
	AU 9643311	A1	19960815	AU 1996-43311	19960201
	AT 161841	E	19980115	AT 1996-101596	19960205
	ES 2112656	T3	19980401	ES 1996-101596	19960205
	US 5705453	A	19980106	US 1996-599340	19960208
	CN 1137523	A	19961211	CN 1996-105733	19960209
PRAI	JP 1995-21383		19950209		
	JP 1996-4963		19960116		

OS MARPAT 125:195645
AB Title compds. [I; R1 = H, alkyl, alkoxy, halo; R2 = H, alkyl, alkanoyl, MeOCH2, MeOCH2CH2; R3 = H, alkyl; R4 = H, alkyl, alkoxy, halo, haloalkoxy, cycloalkoxy, alkylthio, (substituted) phenylamino, N- alkylphenylamino, pyrrolyl, imidazolyl, pyrrolidino, piperidino, PhO], were prepd. Thus, 2-methylindazole-3-carboxylic acid was refluxed 1 h with SOCl2; the product in PhMe was stirred with 5-aminomethyl-2-(4-methylphenoxy)pyridine and Et3n to give N-[6-(4-methylphenoxy)-3-pyridylmethyl]-2-methyl-3-indazolecarboxamide. The latter at 500 ppm gave 100% miticidal activity against Tetranychus urticae eggs.
IT **181071-16-9P 181071-17-0P 181071-18-1P**
181071-19-2P 181071-20-5P 181071-21-6P
181071-22-7P 181071-23-8P 181071-24-9P
181071-25-0P 181071-26-1P 181071-27-2P
181071-28-3P 181071-29-4P 181071-30-7P
181071-31-8P 181071-32-9P 181071-33-0P
181071-34-1P 181071-35-2P 181071-36-3P
181071-37-4P 181071-38-5P 181071-39-6P
181071-40-9P 181071-41-0P 181071-42-1P
181071-43-2P 181071-44-3P 181071-50-1P
181071-51-2P 181071-52-3P 181071-53-4P
181071-54-5P 181071-55-6P 181071-56-7P
181071-57-8P 181071-58-9P 181071-59-0P
181071-60-3P 181071-61-4P 181071-62-5P
181071-63-6P 181071-64-7P 181071-65-8P
181071-66-9P 181071-67-0P 181071-68-1P
181071-69-2P 181071-71-6P 181071-84-1P
181071-85-2P 181071-86-3P 181071-87-4P
181071-88-5P 181071-89-6P 181071-90-9P
181071-91-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of (pyridylmethylaminocarbonyl)indazoles as fungicides, insecticides and miticides)

RN 181071-16-9 CAPLUS

CN 2H-Indazole-3-carboxamide, 2-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-17-0 CAPLUS

CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-(4-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-18-1 CAPLUS

CN 2H-Indazole-3-carboxamide, N-[[6-(4-ethylphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-19-2 CAPLUS

CN 2H-Indazole-3-carboxamide, N-[[6-(3-ethylphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-20-5 CAPLUS

CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[3-(1-methylethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-21-6 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-[3-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-22-7 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-(3-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-23-8 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-methoxyphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-24-9 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-ethoxyphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-25-0 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-butoxyphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-26-1 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[3-(trifluoromethoxy)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-27-2 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-[4-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-28-3 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-[3-(difluoromethoxy)phenoxy]-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-29-4 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-(3-phenoxyphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-30-7 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-fluorophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-31-8 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-32-9 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-chlorophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-33-0 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-bromophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-34-1 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-35-2 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-36-3 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[2-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-37-4 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-([1,1'-biphenyl]-3-yloxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-38-5 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[3-(2-methyl-1,3-dioxolan-2-yl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-39-6 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-acetylphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-40-9 CAPLUS
CN Benzoic acid, 4-[[5-[[[(2-methyl-2H-indazol-3-yl)carbonyl]amino]methyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 181071-41-0 CAPLUS
CN Benzoic acid, 3-[[5-[[[(2-methyl-2H-indazol-3-yl)carbonyl]amino]methyl]-2-pyridinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 181071-42-1 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-[4-(methylthio)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-43-2 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-(3-nitrophenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-44-3 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-cyanophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-50-1 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3,4-dimethylphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-51-2 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3,5-dimethylphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-52-3 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-[3,5-bis(1-methylethyl)phenoxy]-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-53-4 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3,4-dichlorophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-54-5 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(2,4-dichlorophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-55-6 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(3-chloro-4-fluorophenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-56-7 CAPLUS
CN 2H-Indazole-3-carboxamide, 4-chloro-2-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-57-8 CAPLUS
CN 2H-Indazole-3-carboxamide, 5-chloro-2-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-58-9 CAPLUS
CN 2H-Indazole-3-carboxamide, 5-chloro-2-methyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-59-0 CAPLUS
CN 2H-Indazole-3-carboxamide, 5-chloro-2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-60-3 CAPLUS
CN 2H-Indazole-3-carboxamide, 6-chloro-2-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-61-4 CAPLUS
CN 2H-Indazole-3-carboxamide, 2,7-dimethyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-62-5 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-2,7-dimethyl- (9CI) (CA INDEX NAME)



RN 181071-63-6 CAPLUS
CN 2H-Indazole-3-carboxamide, 2,7-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-64-7 CAPLUS
CN 2H-Indazole-3-carboxamide, 2,7-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-65-8 CAPLUS
CN 2H-Indazole-3-carboxamide, 7-chloro-2-methyl-N-[(6-phenoxy-3-

pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-66-9 CAPLUS
CN 2H-Indazole-3-carboxamide, 7-methoxy-2-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-67-0 CAPLUS
CN 2H-Indazole-3-carboxamide, N,2-dimethyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-68-1 CAPLUS
CN 2H-Indazole-3-carboxamide, N-ethyl-2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-69-2 CAPLUS
CN 2H-Indazole-3-carboxamide, N-(methoxymethyl)-2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-71-6 CAPLUS
CN 2H-Indazole-3-carboxamide, N-acetyl-2-methyl-N-[[6-[3-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-84-1 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[(6-phenoxy-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-85-2 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[6-(4-methylphenoxy)-2-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 181071-86-3 CAPLUS

CN 2H-Indazole-3-carboxamide, N-[[6-(4-methoxyphenoxy)-2-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-87-4 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(4-chlorophenoxy)-2-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-88-5 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[6-(4-fluorophenoxy)-2-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-89-6 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[(2-phenoxy-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 181071-90-9 CAPLUS
CN 2H-Indazole-3-carboxamide, N-[[2-(4-chlorophenoxy)-4-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 181071-91-0 CAPLUS
CN 2H-Indazole-3-carboxamide, 2-methyl-N-[[2-(4-methylphenoxy)-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



IT **181071-93-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of (pyridylmethylaminocarbonyl)indazoles as fungicides, insecticides and miticides)
RN 181071-93-2 CAPLUS
CN 3-Pyridinemethanamine, 6-(4-methylphenoxy)- (9CI) (CA INDEX NAME)



L18 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1994:605216 CAPLUS
DN 121:205216
TI Preparation of pyrimidinylaminoalkenyl haloalkyl ketones and analogs as insecticides
IN Sugyama, Hidetoshi; Nezu, Masao; Kusakari, Junpei; Kurihara, Hiroshi; Minoguchi, Naokazu; Yano, Juko; Hirano, Tadami
PA Kumiai Chemical Industry Co, Japan; Ihara Chemical Ind Co
SO Jpn. Kokai Tokkyo Koho, 15
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06135933	A2	19940517	JP 1992-223650	19920731
	JP 3283069	B2	20020520		
PRAI	JP 1992-223650		19920731		

OS MARPAT 121:205216
AB The title compds. R1COCR2:CR3N(Z)R4 [R1 = haloalkyl; R2 = H; R3 = alkyl, (substituted) Ph; R4 = H, alkyl, haloalkyl; Z = (substituted) pyrimidinyl, etc.] are prepd. A mixt. of 2-methoxy-5,5,5-trifluoro-2-penten-4-one and pyrimidine I in acetonitrile was refluxed for 10 h to give pyrimidine deriv. II. II at 500 ppm gave 90 - 100% control of Nilaparvata lugens.
IT **157921-23-8P 157921-24-9P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)
RN 157921-23-8 CAPLUS
CN 2-Hepten-4-one, 5,5,6,6,7,7,7-heptafluoro-2-[methyl[(6-phenoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 157921-24-9 CAPLUS
CN 3-Penten-2-one, 1,1,1-trifluoro-4-[methyl[(6-phenoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



L18 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1991:492085 CAPLUS
DN 115:92085
TI Preparation of pyridylalkylamine derivatives as insecticides
IN Ishimitsu, Keiichi; Suzuki, Junji; Ohishi, Haruhito; Yamada, Tomio; Hatano, Renpei; Takakusa, Nobuo; Mitsui, Jun
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9104965	A1	19910418	WO 1990-JP1282	19901004
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	ZA 9007775	A	19910731	ZA 1990-7775	19900928
	CA 2041670	AA	19910407	CA 1990-2041670	19901004
	CA 2041670	C	19970318		
	AU 9065117	A1	19910428	AU 1990-65117	19901004
	AU 633991	B2	19930211		
	EP 456826	A1	19911121	EP 1990-914758	19901004
	EP 456826	B1	19990107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	HU 57191	A2	19911128	HU-1990-7896	19901004
	HU 214992	B	19981228		
	BR 9006961	A	19911217	BR 1990-6961	19901004
	JP 04154741	A2	19920527	JP 1990-264968	19901004
	JP 2926954	B2	19990728		
	RO 112865	B1	19980130	RO 1990-147641	19901004
	AT 175405	E	19990115	AT 1990-914758	19901004
	ES 2127718	T3	19990501	ES 1990-914758	19901004
	HU 220083	B	20011028	HU 1998-2249	19901004
	CN 1050714	A	19910417	CN 1990-108265	19901006
	CN 1056958	B	20001004		
	IL 98014	A1	19960804	IL 1991-98014	19910501
	RU 2038352	C1	19950627	RU 1991-4895590	19910605
	US 5304566	A	19940419	US 1991-700165	19910709
	LV 10155	B	19950820	LV 1992-617	19921230
	LT 3209	B	19950327	LT 1993-342	19930213
	US 5612358	A	19970318	US 1993-117470	19930907
PRAI	JP 1989-259966	A	19891006		
	JP 1989-336231	A	19891227		
	JP 1990-56611	A	19900309		
	JP 1990-115246	A	19900502		
	JP 1990-196258	A	19900726		
	WO 1990-JP1282	A	19901004		
	US 1991-700165	A1	19910709		

OS MARPAT 115:92085
AB The title compds. [I; R1 = H; substituent; R2 = H, (substituted) (thio)carbamoyl, sulfamoyl, (substituted) C1-5 alkyl, C2-5 alkenyl, alkynyl etc.; R3 = H, (substituted) C1-5 alkyl, C2-5 alkenyl, alkynyl, C3-8 cycloalkyl, etc., R4 = cyano, NO2; X = (substituted) C1-3 alkylene, alkylidene; Z = CH, N] or their salts are prepd. A mixt. of amine II 4.2, EtCOCH2NO2 3.5, and p-MeC6H4SO3H 0.1 g in MePh was refluxed to give 4.1 g

III, which killed 100% cotton aphids and green rice leafhopper at 125 ppm. Also prepd. and tested were 111 addnl. I.

IT **135410-75-2P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)

RN 135410-75-2 CAPLUS

CN Ethanimidamide, N-cyano-N'-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1991:164015 CAPLUS
DN 114:164015
TI Preparations of (pyridylalkyl)diaminoethylenes as insecticides
IN Uneme, Hideki; Minamida, Isao; Okauchi, Tetsuo
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 392560	A2	19901017	EP 1990-107120	19900412
	EP 392560	A3	19920108		
	EP 392560	B1	19951227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 94027	A1	19950315	IL 1990-94027	19900406
	BR 9001734	A	19910604	BR 1990-1734	19900411
	JP 03169861	A2	19910723	JP 1990-97363	19900411
	IN 170550	A	19920411	IN 1990-MA269	19900411
	CA 2014490	AA	19901014	CA 1990-2014490	19900412
	US 5438065	A	19950801	US 1990-507776	19900412
	AT 132139	E	19960115	AT 1990-107120	19900412
	ES 2081314	T3	19960301	ES 1990-107120	19900412
	HU 53780	A2	19901228	HU 1990-2438	19900413
	HU 207202	B	19930329		
	CN 1046896	A	19901114	CN 1990-102111	19900414
	CN 1036112	B	19971015		
PRAI	JP 1989-95580		19890414		
	JP 1989-201980		19890802		

OS MARPAT 114:164015
AB Title compds. R1(CH2)nNR2C(NR3R4):CXCHR5Y (R1 = (substituted) heterocyclyl; R2, R3, R4 = H, (substituted) hydrocarbyl, R3R4N = heterocyclyl; R5 = H, (substituted) hydrocarbyl, (substituted) heterocyclyl; X = electron attractant; Y = R6O, R6 = H, (substituted) hydrocarbyl, -heterocyclyl, (substituted) amino), etc.; n = 0, 1) or a salt thereof, are prepd. 1-[N-(6-Chloro-3-pyridylmethyl)-N-methylamino]-1-(methylamino)-2-nitroethylene, aq. CH2O, aq. Me2NH and MeCN were stirred at room temp. for 8.5 h to give the pyridine deriv. I. I at 500 and 100 ppm resulted in 100% mortality against Nilaparvata lugens and Aphis gossypii, resp.
IT **133077-63-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)
RN 133077-63-1 CAPLUS
CN 2-Propen-1-ol, 3-[[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]ethylamino]-3-(methylamino)-2-nitro- (9CI) (CA INDEX NAME)


NO2
Et
N
O
HO
CH2
C
C
N
CH2
Cl
NHMe

L18 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1990:572041 CAPLUS
DN 113:172041
TI Preparation of tetrahydropyrimidines as pesticides
IN Uneme, Hideki; Minamida, Isao; Higuchi, Noriko; Okauchi, Tetsuo
PA Takeda Chemical Industries, Ltd., Japan
SO Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 366085	A2	19900502	EP 1989-119748	19891024
	EP 366085	A3	19901128		
	EP 366085	B1	19960417		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IN 170284	A	19920307	IN 1989-MA769	19891018
	JP 03128361	A2	19910531	JP 1989-273035	19891019
	JP 3038555	B2	20000508		
	AT 136890	E	19960515	AT 1989-119748	19891024
	ES 2085857	T3	19960616	ES 1989-119748	19891024
	CA 2001497	AA	19900426	CA 1989-2001497	19891025
	HU 53489	A2	19901128	HU 1989-5441	19891025
	HU 206953	B	19930301		
	US 5084459	A	19920128	US 1989-426177	19891025
	CN 1042149	A	19900516	CN 1989-108779	19891026
	CN 1031265	B	19960313		
	BR 8905476	A	19900529	BR 1989-5476	19891026
	IN 173028	A	19940129	IN 1991-MA537	19910716
	IN 173027	A	19940129	IN 1991-MA538	19910716
	CN 1102828	A	19950524	CN 1994-115344	19940916
PRAI	JP 1988-270064	A	19881026		
	JP 1989-184312	A	19890717		
	IN 1989-MA769	A1	19891018		

OS MARPAT 113:172041
AB Title compds. I [R1-R4 = H, (substituted) hydrocarbyl, (substituted) heterocyclyl; X = an electron attracting group] or their salts are prepd. 1-[N-(6-chloro-3-pyridylmethyl)-N-methylamino]-1-(methylamino)-2-nitroethylene, EtOH and THF were added to formalin to give I (R1 = 6-chloro-3-pyridylmethyl; R2 = R3 = R4 = Me; X = O2N) (II). II at 5 mg applied to stem and leaves of rice plant seedlings at the 2-leaf stage in paper nursery pots at 10 mL/pot, resulted in 100% mortality to Nilaparvata lugens 3rd-instar larvae after 7 days.
IT **129950-07-8P 129950-24-9P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)
RN 129950-07-8 CAPLUS
CN 4-Pyrimidinamine, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-N-ethyl-1,2,3,6-tetrahydro-1,3-dimethyl-5-nitro- (9CI) (CA INDEX NAME)



RN 129950-24-9 CAPLUS
CN 4-Pyrimidinamine, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-1,2,3,6-tetrahydro-1,3-dimethyl-5-nitro- (9CI) (CA INDEX NAME)



L18 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1990:55855 CAPLUS
DN 112:55855
TI Preparation of [(5-pyrazolylcarboxamido)alkyl]pyridine derivatives and insecticidal, miticidal, and fungicidal compositions containing them as active ingredients
IN Okada, Itaru; Suzuki, Shigeru; Okui, Shuko; Takahashi, Yoji; Fukuchi, Toshiki; Nakajima, Tetsuo
PA Mitsubishi Kasei Corp., Japan
SO Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 329020	A1	19890823	EP 1989-102263	19890209
	EP 329020	B1	19910130		
	R: CH, DE, ES, FR, GB, IT, LI				
	JP 02062876	A2	19900302	JP 1989-25493	19890203
	JP 2751309	B2	19980518		
	BR 8900743	A	19891017	BR 1989-743	19890215
	US 4968805	A	19901106	US 1989-310591	19890215
PRAI	JP 1988-33383		19880216		
	JP 1988-121295		19880518		

OS CASREACT 112:55855; MARPAT 112:55855
AB The title compds. [I; R1 = C1-4 alkyl, PhCH2; R2 = H, C1-4 alkyl; X = H, halo, C1-4 alkyl; or R2X = Q, Q1; R5 = H, C1-3 alkyl; R3 = H, C1-4 alkyl; R4 = H, halo, C1-5 alkyl, C1-4 (halo)alkoxy, C1-4 alkylthio, CF3, (alkyl)phenyl, (un)substituted PhO or PhS; or adjacent R4s = Q2; R7 = H, Me; l = 0, 1; m = 1-3], useful as insecticides, miticides, and agrochem. fungicides, are prepd. by condensation of pyrazole-5-carboxylic acids (II; Z = OH, OMe, OEt, OPr) with (aminoalkyl)pyridines (III). Thus, treatment of 4-chloro-1,3-dimethylpyrazole-5-carboxylic acid with SOCl2 under reflux followed by amidation with 5-(aminomethyl)-2-tert-butylpyridine in PhMe contg. Et3N at 0-10.degree. gave N-[(6-tert-butyl-3-pyridyl)methyl]-4-chloro-1,3-dimethyl-5-pyrazolecarboxamide. One hundred and ten I were prepd. Fifty-nine I at 500 ppm showed 100% miticidal and ovicidal activity against Tetranychus urticae on a kidney bean leaf.
IT **124800-37-9**, 5-Aminomethyl-2-(4-chlorophenoxy)pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with pyrazolecarboxylic acid deriv.)
RN 124800-37-9 CAPLUS
CN 3-Pyridinemethanamine, 6-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



IT **124800-38-0P 124800-40-4P 124800-42-6P**
124800-43-7P 124800-44-8P 124800-45-9P
124800-46-0P 124800-47-1P 124800-48-2P
124800-49-3P 124800-50-6P 124800-51-7P
124800-52-8P 124800-53-9P 124800-54-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide, miticide, and fungicide)

RN 124800-38-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 4-chloro-3-ethyl-1-methyl-N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 124800-40-4 CAPLUS

CN 3-Cyclopentapyrazolecarboxamide, N-[[6-(3,4-dichlorophenoxy)-3-pyridinyl]methyl]-2,4,5,6-tetrahydro-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 124800-42-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 4-chloro-3-ethyl-1-methyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 124800-43-7 CAPLUS

CN 3-Cyclopentapyrazolecarboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-2,4,5,6-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 124800-44-8 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-2,4,5,6-tetrahydro-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 124800-45-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-1,3,4-trimethyl- (9CI) (CA INDEX NAME)



RN 124800-46-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-bromo-N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 124800-47-1 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-N-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-3-ethyl-1-methyl- (9CI) (CA INDEX NAME)



RN 124800-48-2 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-2,6-dimethyl-N-[[6-[4-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 124800-49-3 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-2,6-dimethyl-N-[[6-(4-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 124800-50-6 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-3-ethyl-N-[[6-(4-methoxyphenoxy)-3-pyridinyl]methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 124800-51-7 CAPLUS

CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-N-[[6-(4-methoxyphenoxy)-3-pyridinyl]methyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 124800-52-8 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-N-[[6-(4-methoxyphenoxy)-3-pyridinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 124800-53-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 4-chloro-3-ethyl-1-methyl-N-[[6-(4-methylphenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 124800-54-0 CAPLUS
CN 3-Cyclopentapyrazolecarboxamide, 2,4,5,6-tetrahydro-2,6-dimethyl-N-[[6-(4-nitrophenoxy)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 1986:224896 CAPLUS
DN 104:224896
TI Nitromethylene derivatives, intermediates, and their preparation as insecticides
IN Shiokawa, Kozo; Tsuboi, Shinichi; Kagabu, Shinzo; Moriya, Koichi
PA Nihon Tokushu Noyaku Seizo K. K., Japan
SO Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 163855	A1	19851211	EP 1985-104254	19850409
	EP 163855	B1	19890621		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 60218386	A2	19851101	JP 1984-72966	19840413
	JP 04060114	B4	19920925		
	JP 61012682	A2	19860121	JP 1984-132943	19840629
	JP 05082391	B4	19931118		
	AT 44145	E	19890715	AT 1985-104254	19850409
	JP 05017447	A2	19930126	JP 1991-182863	19910629
	JP 05047539	B4	19930719		
	JP 06172346	A2	19940621	JP 1993-166278	19930611
	JP 2539159	B2	19961002		
PRAI	JP 1984-72966		19840413		
	JP 1984-132943		19840629		
	EP 1985-104254		19850409		

OS CASREACT 104:224896
AB Nitromethylene derivs. of imidazolidines, perhydropyrimidines, and -1,3-diazepines I (R1 = H, alkyl; R2 = substituted pyridinyl; n = 0-3; m = 1-3) were prepd. Thus, 16.2 g 2-chloro-5-(chloroemthyl)pyridine in MeCN was added dropwise to 18 g (CH2NH2)2 in MeCN followed by stirring 1 h at room temp. and 2 h at 40.degree. to give 16 g N-[(2-chloro-5-pyridinyl)methyl]-1,2-ethanediamine. The latter (18.6 g) and 16.5 g (MeS)2C:CHNO2 were cyclocondensed by heating at 50.degree. in MeOH to give 19 g 2-(nitromethylene)imidazolidine II. At 8 ppm II gave 100% kill of organophosphate-resistant Nephotettix cincticeps.
IT **101990-59-4P 101990-60-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclocondensation of, with nitroacrolein mercaptal)
RN 101990-59-4 CAPLUS
CN 1,2-Ethanediamine, N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 101990-60-7 CAPLUS
CN 1,3-Propanediamine, N-[(6-phenoxy-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)


PhO
N
CH2—NH—(CH2)3—NH2

```
=> d his

     (FILE 'HOME' ENTERED AT 14:06:23 ON 01 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 14:06:28 ON 01 MAY 2003
L1                STRUCTURE UPLOADED
L2              0 S L1 SSS SAM
L3                STRUCTURE UPLOADED
L4              0 S L3 SSS SAM
L5                SCREEN 2026 OR  2039 OR  2016 OR  2045
L6                STRUCTURE UPLOADED
L7                QUE L6 NOT L5
L8              0 S L7 SSS SAM
L9                SCREEN 2026 OR  2039 OR  2016 OR  2045
L10               STRUCTURE UPLOADED
L11               QUE L10 NOT L9
L12             1 S L11 SSS SAM
L13               SCREEN 2026 OR  2039 OR  2016 OR  2045
L14               STRUCTURE UPLOADED
L15               QUE L14 NOT L13
L16             1 S L15 SSS SAM
L17           280 S L15 SSS FUL

     FILE 'CAPLUS' ENTERED AT 14:25:07 ON 01 MAY 2003
L18            24 S L17

     FILE 'CAOLD' ENTERED AT 14:26:00 ON 01 MAY 2003

=> s l17
L19             0 L17

=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.40     270.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00     -15.62

STN INTERNATIONAL LOGOFF AT 14:26:13 ON 01 MAY 2003
```